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1.1: DEFINITION OF CKD
1.1.1: CKD is defined as abnormalities of kidney struc-
ture or function, present for 43 months, with
implications for health (Table 2). (Not Graded)
RATIONALE
The definition of CKD remains intact, but we have clarified
the classification and risk stratification as indicated below.
The addition of ‘with implications for health’ is intended to
reflect the notion that a variety of abnormalities of kidney
structure or function may exist, but not all have implications
for health of individuals, and therefore need to be
contextualized.
Kidney damage refers to a broad range of abnormalities
observed during clinical assessment, which may be insensitive
and non-specific for the cause of disease but may precede
reduction in kidney function (Table 2). Excretory, endocrine
and metabolic functions decline together in most chronic
kidney diseases. GFR is generally accepted as the best overall
index of kidney function. We refer to a GFR o60ml/min/
1.73m2 as decreased GFR (Table 2) and a GFRo15ml/min/
1.73m2 as kidney failure. AKI may occur in patients with
CKD and hasten the progression to kidney failure.14
Complications include drug toxicity, metabolic and
endocrine complications, increased risk for CVD, and a
variety of other recently recognized complications, including
infections, frailty, and cognitive impairment.15–18 Complica-
tions may occur at any stage, often leading to death without
progression to kidney failure. Complications may also arise
from adverse effects of interventions to prevent or treat the
disease and associated comorbidity.
Criteria for CKD
Defining terms: The following section aims to define specific
terms and concepts so as to ensure clarity among all users.
In addition, the rationale for including these terms is included.
Table 3 provides a justification for the criteria for CKD. The
criteria for definition of CKD are objective and can be
ascertained by means of simple laboratory tests without
identification of the cause of disease, thereby enabling
detection of CKD by non-nephrologist physicians and other
health professionals.
Duration 43 Months
Kidney diseases may be acute or chronic. We explicitly but
arbitrarily define duration of 43 months (490 days) as
delineating ‘‘chronic’’ kidney disease. The rationale for
defining chronicity is to differentiate CKD from acute kidney
diseases (such as acute GN), including AKI, which may
require different interventions, and have different etiologies
and outcomes.7 We did not define acute kidney disease
(AKD) because there does not appear be an evidence base for
a precise definition.
The duration of kidney disease may be documented or
inferred based on the clinical context. For example, a patient
with decreased kidney function or kidney damage in the
midst of an acute illness, without prior documentation of
kidney disease, may be inferred to have AKI. Resolution over
days to weeks would confirm the diagnosis of AKI. A patient
with similar findings in the absence of an acute illness may be
inferred to have CKD, and if followed over time would be
confirmed to have CKD. In both cases, repeat ascertainment
of kidney function and kidney damage is recommended for
accurate diagnosis. The timing of the evaluation depends on
clinical judgment, with earlier evaluation for the patients
suspected of having AKI and later evaluation for the patient
suspected of having CKD. For further details on the
Evaluation of CKD, see Chapter 1.4.
Reversibility. Most kidney diseases do not have symptoms
or findings until later in their course and are detected only
when they are chronic. Most causes of CKD are irreversible
with a life-long course, and treatment aimed at slowing
progression to kidney failure. However, chronicity is not
synonymous with irreversibility. In some cases, CKD is
entirely reversible, either spontaneously or with treatment,
and in other cases, treatment can cause partial regression of
kidney damage and improvement in function (e.g., immuno-
suppressive therapies for GN). Even kidney failure may be
reversed with transplantation. Because of the long course of
most cases of CKD, patients often have one or more episodes
of AKI, superimposed upon CKD.
Decreased GFR
The kidney has many functions, including excretory,
endocrine and metabolic functions. The GFR is one compo-
nent of excretory function, but is widely accepted as the best
overall index of kidney function because it is generally
reduced after widespread structural damage and most other
kidney functions decline in parallel with GFR in CKD.
We chose a threshold of GFR o60ml/min/1.73m2 (GFR
categories G3a-G5) for 43 months to indicate CKD. A GFR
o60ml/min/1.73m2 is less than half of the normal value in
young adult men and women of approximately 125ml/min/
1.73m2. Figure 2 shows a compilation of GFR measurements
in apparently healthy men and women in the US and Europe
by age from more than 40 years ago.20 The age-associated
GFR decline is observed in longitudinal as well as cross
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Table 2 | Criteria for CKD (either of the following present for 43 months)
Markers of kidney damage (one or more) Albuminuria (AERZ30 mg/24 hours; ACRZ30 mg/g [Z3 mg/mmol])
Urine sediment abnormalities
Electrolyte and other abnormalities due to tubular disorders
Abnormalities detected by histology
Structural abnormalities detected by imaging
History of kidney transplantation
Decreased GFR GFRo60 ml/min/1.73 m2 (GFR categories G3a-G5)
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
Table 3 | Criteria for definition of CKD19
Criteria Comment
Duration 43 months, based on documentation or
inference
Duration is necessary to distinguish chronic from acute kidney diseases
K Clinical evaluation will often enable documentation or inference of duration
K Documentation of duration is usually not declared in epidemiologic studies
GFR o60ml/min/1.73m2 (GFR categories G3a-G5) GFR is the best overall index of kidney function in health and disease
K The normal GFR in young adults is approximately 125ml/min/1.73m2. GFR
o15ml/min/1.73m2 (GFR category G5) is defined as kidney failure
K Decreased GFR can be detected by current estimating equations for GFR based
on SCr or cystatin C but not by SCr or cystatin C alone
K Decreased eGFR can be confirmed by measured GFR, if required
Kidney damage as defined by structural abnormalities or
functional abnormalities other than decreased GFR
Albuminuria as a marker of kidney damage [increased glomerular permeability],
urine AER Z30mg/24 hours, approximately equivalent to urine ACRZ30mg/g
(Z3mg/mmol)*
K The normal urine ACR in young adults is o10mg/g (o1mg/mmol)
K Urine ACR 30-300mg/g (3–30mg/mmol; category A2) generally corresponds to
‘‘microalbuminuria,’’ now referred to as ‘‘moderately increased’’
K Urine ACR 4300mg/g (430mg/mmol; category A3) generally corresponds to
‘‘macroalbuminuria,’’ now termed ‘‘severely increased’’
K Urine ACR42200mg/g (220mg/mmol) may be accompanied by signs and
symptoms of nephrotic syndrome (e.g., low serum albumin, edema, and high
serum cholesterol)
K Threshold value corresponds approximately to urine reagent strip values of trace
or +, depending on urine concentration.
K High urine ACR can be confirmed by urine albumin excretion in a timed urine
collection expressed as AER
Urinary sediment abnormalities as markers of kidney damage
K Isolated non-visible (microscopic) hematuria with abnormal RBC morphology
(anisocytosis) in GBM disorders
K RBC casts in proliferative glomerulonephritis
K WBC casts in pyelonephritis or interstitial nephritis
K Oval fat bodies or fatty casts in diseases with proteinuria
K Granular casts and renal tubular epithelial cells in many parenchymal diseases
(non-specific)
Renal tubular disorders
K Renal tubular acidosis
K Nephrogenic diabetes insipidus
K Renal potassium wasting
K Renal magnesium wasting
K Fanconi syndrome
K Non-albumin proteinuria
K Cystinuria
Pathologic abnormalities detected by histology or inferred (examples of causes)
K Glomerular diseases (diabetes, autoimmune diseases, systemic infections, drugs,
neoplasia)
K Vascular diseases (atherosclerosis, hypertension, ischemia, vasculitis, thrombotic
microangiopathy)
K Tubulointerstitial diseases (urinary tract infections, stones, obstruction, drug
toxicity)
K Cystic and congenital diseases
20 Kidney International Supplements (2013) 3, 19–62
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sectional studies, but varies substantially among individuals
within the population.21 More recent data in kidney donors
confirm these general trends.22,23 Limited data are available
for non-whites in the US and Europe or in other countries,
although data suggest that the normal range for measured
GFR and the age-associated decline is similar.24–26
A GFR o60ml/min/1.73m2 can be detected by routine
laboratory testing. Current estimating equations for GFR
(eGFR) based on serum creatinine (SCr), but not SCr alone,
are sensitive for detecting measured GFRo60ml/min/
1.73m2.27 A decreased eGFR using SCr can be confirmed
by GFR estimation using an alternative filtration marker
(cystatin C) or GFR measurement, as necessary.
A GFRo60ml/min/1.73m2 is associated with a higher
risk of complications of CKD than in subjects with CKD and
conserved GFR. The causal mechanisms underlying these
associations are not fully understood. We consider three main
types of complications, which are of relevance to all patients
with CKD and reduced GFR, irrespective of country, age or
etiology:
Drug toxicity. Altered pharmacokinetics of drugs excreted
by the kidney and an increased risk of drug-interactions are
common and require adjustment in the dosage of many
drugs (see Chapter 4.4).13 At lower GFR, altered pharmaco-
kinetics and pharmacodynamics of drugs not excreted by the
kidney may also be observed. Errors in drug dosing are
common in patients with CKD and may be associated with
toxicity to the kidney (resulting in AKI) or systemic toxicity,
resulting in threats to patient safety.
Metabolic and endocrine complications. As GFR declines a
variety of complications reflecting loss of endocrine or
exocrine function of the kidneys develop including anemia,
acidosis, malnutrition, bone and mineral disorders (des-
cribed in Chapters 3 and 4).
Risk of CVD and death. A meta-analysis by the CKD Prog-
nosis Consortium demonstrated associations of eGFR o60ml/
min/1.73m2 with subsequent risk of all-cause and cardio-
vascular mortality, kidney failure, AKI, and CKD progression in
the general population and in populations with increased risk
for CVD.3-5 Figure 3 shows the relationship for total and
cardiovascular mortality in general population cohorts. The
risk for all outcomes was relatively constant between eGFR
of 75-105ml/min/1.73m2, with a suggestion of a U-shaped
curve for total mortality. The increased relative risk (RR) for
all outcomes was significant for eGFR of o60ml/min/1.73m2.
Kidney Damage
Damage to the kidney can be within the parenchyma,
large blood vessels or collecting systems, and is most often
inferred from markers rather than direct examination of
kidney tissue. The markers of kidney damage often provide
a clue to the likely site of damage within the kidney and in
association with other clinical findings, the cause of kidney
disease.
Proteinuria. Proteinuria is a general term for the presence
of increased amounts of protein in the urine. Proteinuria may
reflect abnormal loss of plasma proteins due to a) increased
glomerular permeability to large molecular weight proteins
(albuminuria or glomerular proteinuria), b) incomplete
tubular reabsorption of normally filtered low-molecular-
weight proteins (tubular proteinuria), or c) increased plasma
concentration of low-molecular-weight proteins (overpro-
duction proteinuria, such as immunoglobulin light chains).
Proteinuria may also reflect abnormal loss of proteins derived
from the kidney (renal tubular cell constituents due to
tubular damage) and lower urinary tract. Albuminuria,
tubular proteinuria and renal tubular cell constituents
are pathognomonic of kidney damage. In addition, findings
Table 3 | Continued
Criteria Comment
Structural abnormalities as markers of kidney damage detected by imaging
(ultrasound, computed tomography and magnetic resonance with or without contrast,
isotope scans, angiography)
K Polycystic kidneys
K Dysplastic kidneys
K Hydronephrosis due to obstruction
K Cortical scarring due to infarcts, pyelonephritis or associated with vesicoureteral
reflux
K Renal masses or enlarged kidneys due to infiltrative diseases
K Renal artery stenosis
K Small and hyperechoic kidneys (common in more severe CKD due to many
parenchymal diseases)
History of kidney transplantation
K Kidney biopsies in most kidney transplant recipients have histopathologic
abnormalities even if GFR is 460ml/min/1.73m2 (GFR categories G1-G2) and
ACR is o30mg/g (o3mg/mmol)
K Kidney transplant recipients have an increased risk for mortality and kidney
failure compared to populations without kidney disease
K Kidney transplant recipients routinely receive subspecialty care
Abbreviations: ACR, albumin-to-creatinine ratio; AER, albumin excretion rate; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GBM, glomerular
basement membrane; GFR, glomerular filtration rate; RBC, red blood cell; SCr, serum creatinine; WBC, white blood cell.
*For conversion, see Table 7, Chapter 1
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from experimental and clinical studies have suggested an
important role for proteinuria in the pathogenesis of disease
progression of CKD.28
Albuminuria. Albuminuria refers to abnormal loss of
albumin in the urine. Albumin is one type of plasma protein
found in the urine in normal subjects and in larger quantity
in patients with kidney disease.
For a number of reasons, clinical terminology is changing
to focus on albuminuria rather than proteinuria: a) albumin
is the principal component of urinary protein in most kidney
diseases; recent recommendations for measurement of urine
proteins emphasize quantification of albuminuria rather than
total protein; b) recent epidemiologic data from studies
around the world demonstrate a strong graded relationship
of the quantity of urine albumin with both kidney and CVD
risk; and c) later recommendations in these guidelines classify
kidney disease by level of albuminuria. In this guideline, we
will refer to proteinuria when discussing general concepts
and will refer either to total protein, albumin or other specific
proteins when discussing measurements, patterns, and
interpretation of proteinuria.
Albuminuria is a common but not uniform finding in
CKD. It is the earliest marker of glomerular diseases,
including diabetic glomerulosclerosis, where it generally
appears before the reduction in GFR. It is a marker of
hypertensive nephrosclerosis but may not appear until after
the reduction in GFR. It is often associated with underlying
hypertension, obesity, and vascular disease, where the
underlying renal pathology is not known.
Normative values for albuminuria and proteinuria are
generally expressed as the urinary loss rate. The urinary loss
rate of albumin and protein has commonly been referred to
as AER and protein excretion rate (PER), respectively,
although in the strict physiological sense they are not
excreted. The terms AER and PER will be retained herein.
We chose a threshold for urinary AER of Z30mg/
24 hours sustained for 43 months to indicate CKD.
This value is considered to be approximately equivalent
to an ACR in a random untimed urine sample of Z30mg/g
or Z3mg/mmol. The rationale for this threshold is as
follows:
K An AER of Z30mg/24 hours (ACRZ30mg/g [Z3mg/
mmol]) is greater than 3 times the normal value in young
adult men and women of approximately 10mg/24 hours
(ACR 10mg/g or 1mg/mmol).
K An AER of Z30mg/24 hours (ACRZ30mg/g [Z3mg/
mmol]) may sometimes be detectable as ‘trace’ using a urine
reagent strip, depending on urine concentration, but this is
not a consistent finding until AER exceeds approximately
300mg/24 hours (ACRZ300mg/g [Z30mg/mmol]). As
described later, trace or positive reagent strip values/readings
can be confirmed by ACR, and an elevated ACR can be
confirmed by urine AER in a timed urine collection, as
necessary.
K An AERZ30mg/24 hours (ACRZ30mg/g [Z3mg/
mmol]) is associated with an increased risk for
complications of CKD. A meta-analysis by the CKD
Prognosis Consortium demonstrated associations of an
ACRZ30mg/g (Z3mg/mmol) or reagent strip 1þ
protein with subsequent risk of all-cause and cardio-
vascular mortality, kidney failure, AKI, and CKD
progression in the general population and in populations
with increased risk for CVD3-5 (Figure 4).
Figure 2 |Normal values for GFR by age. GFR is shown for men (Panel a) and women (Panel b) of various ages, with the GFR measured as
the urinary clearance of inulin. The horizontal line indicates a GFR value of 60ml/min/1.73m2, which is the threshold for the definition of
CKD. Solid lines represent the mean value of GFR per decade of age, and dashed lines represent the value 1 SD from the mean value of GFR
per decade of age. CKD, chronic kidney disease; GFR, glomerular filtration rate; SD, standard deviation. Adapted with permission from
Wesson L.20 Physiology of the Human Kidney. Grune & Stratton: New York, 1969.
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Urine sediment abnormalities. Formed elements, such as
cells, casts, crystals, and microorganisms may appear in the
urine sediment in a variety of disorders of the kidney and
urinary tract, but renal tubular cells, red blood cell (RBC)
casts, white blood cell (WBC) casts, coarse granular casts,
wide casts, and large numbers of dysmorphic RBCs are
pathognomonic of kidney damage.
Electrolyte and other abnormalities due to tubular disorders.
Abnormalities of electrolytes and other solutes may result from
disorders of renal tubular reabsorption and secretion. These
syndromes are uncommon but pathognomonic of kidney
disease. Often the diseases are genetic without underlying
pathologic abnormalities. Other diseases are acquired, due to
drugs or toxins, and are usually with prominent tubular
pathologic lesions.
Pathologic abnormalities directly observed in kidney tissue
obtained by biopsy. Evidence of abnormalities of renal
parenchyma in kidney biopsies irrespective of eGFR or other
markers of kidney damage must be acknowledged as an
important parameter in defining kidney damage. The
pathologic classification of diseases of the renal parenchyma
reflects the localization of the disease to glomeruli, vessels,
tubules and interstitium, or cysts. Renal biopsies are
performed in the minority of CKD patients.
Imaging abnormalities. Imaging techniques allow the
diagnosis of diseases of the renal structure, vessels and/or
collecting systems. Thus, patients with significant structural
abnormalities are considered to have CKD if the abnor-
mality persists for greater than 3 months (note that this does
not include simple cysts and clinical context is required
for action).
History of kidney transplantation. Kidney transplant re-
cipients are defined as having CKD, irrespective of the level of
GFR or presence of markers of kidney damage. The rationale
Figure 3 |Relationship of eGFR with mortality. HRs and 95% CIs
for all-cause (a) and cardiovascular mortality (c) according to
spline eGFR. HRs and 95% CIs (shaded areas) are adjusted for ACR,
age, sex, ethnic origin, history of CVD, systolic BP, diabetes,
smoking, and total cholesterol. The reference (diamond) was eGFR
95ml/min/1.73 m2 and ACR 5mg/g (0.6mg/mmol), respectively.
Circles represent statistically significant and triangles represent
not significant. ACR, albumin-to-creatinine ratio; BP, blood
pressure; CI, confidence interval; CVD, cardiovascular disease;
eGFR, estimated glomerular filtration rate; HR, hazard ratio.
Reprinted from The Lancet, vol 375, Matshushita K, van de Velde
M, Astor BC, et al.4 Association of estimated glomerular filtration
rate and albuminuria with all-cause and cardiovascular mortality
in general population cohorts: a collaborative meta-analysis, p.
2073-2081, 2010, with permission from Elsevier; accessed http://
download.thelancet.com/pdfs/journals/lancet/
PIIS0140673610606745.pdf
Figure 4 |Relationship of albuminuria with mortality. HRs and
95% CIs for all-cause (b) and cardiovascular mortality (d)
according to ACR. HRs and 95% CIs (shaded areas) are adjusted for
age, sex, ethnic origin, history of CVD, systolic BP, diabetes,
smoking, and total cholesterol and spline eGFR. The reference
(diamond) was ACR 5mg/g (0.6mg/mmol) and eGFR 95ml/min/
1.73 m2, respectively. Circles represent statistically significant and
triangles represent not significant. ACR plotted in mg/g. To
convert ACR in mg/g to mg/mmol multiply by 0.113. Approximate
conversions to mg/mmol are shown in parentheses. ACR,
albumin-to-creatinine ratio; BP, blood pressure; CI, confidence
interval; CVD, cardiovascular disease; eGFR, estimated glomerular
filtration rate; HR, hazard ratio. Reprinted from The Lancet, vol
375, Matshushita K, van de Velde M, Astor BC, et al.4 Association of
estimated glomerular filtration rate and albuminuria with all-cause
and cardiovascular mortality in general population cohorts: a
collaborative meta-analysis, p. 2073-2081, 2010, with permission
from Elsevier; accessed http://download.thelancet.com/pdfs/
journals/lancet/PIIS0140673610606745.pdf
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for this designation is that biopsies in kidney trans-
plant recipients reveal pathologic abnormalities even in
patients without decreased GFR or albuminuria. Kidney
transplant recipients have an increased risk of mortality and
kidney outcomes compared to the general population and
they require specialized medical management.29
Implications for Health
CKD is associated with a wide range of complications leading
to adverse health outcomes. For some complications, the
causal pathway between kidney disease and adverse outcomes
is well-known. For these complications, there are clinical
practice guidelines for testing and treatment for modifiable
factors to prevent adverse outcomes. Since 2002 a large
number of epidemiologic studies have linked decreased GFR
and albuminuria to the risk of adverse health outcomes not
previously identified as CKD complications. The exploration
of the mechanisms for the relationships of CKD with
these complications is a rapidly growing topic for basic
and clinical research. Because of the high prevalence,
adverse outcomes, and high cost of CKD, especially kidney
failure, some countries have developed public health
programs for early identification and treatment of CKD
and its complications. The effectiveness of these programs is
being evaluated.
Implications for Clinical Practice and Public Policy
CKD was first defined in the 2002 KDOQI Guidelines and
endorsed at subsequent KDIGO Controversies Conferences
with minor modifications.30,31 The definition of CKD proposed
here is intended for use in clinical practice, research and public
health, and has not changed. Thus, the updated version does
not change any of the initiatives that have been commenced
with respect to public policy. We recognize the variation around
the world regarding measurement of urine albumin versus total
protein in clinical practice, and we anticipate variation in
implementation of the guideline until more widespread
dissemination of the guideline has occurred. For additional
discussion about methods for ascertainment of urine albumin
versus total protein, see Recommendation 1.4.4 (Evaluation of
albuminuria). The implications of highlighting the importance
of albuminuria for general practitioners in evaluation and
prognostication may help with identification and care planning.
Nonetheless, a number of concerns about the definition remain,
which are clarified below.30,32–36
Areas of Controversy, Confusion, or Non-consensus and
Clarification of Issues and Key Points
General concerns:
a) The use of single thresholds without consideration of
patient specific factors
The use of single thresholds to define decreased GFR and
increased AER, without consideration for cause of disease,
age, sex, race-ethnicity and clinical context is consistent with
the use of single thresholds for disease markers to define
other chronic non-communicable diseases, such as hyperten-
sion, diabetes, and hypercholesterolemia, that primarily affect
the elderly and are associated with an increased risk for
cardiovascular mortality. Biologic variability and error in
ascertainment of GFR and AER can lead to misclassification
and false negative and false positive diagnosis. Furthermore,
these single thresholds appear to differentiate groups of
individuals and outcomes, irrespective of specific patient
characteristics in a multitude of studies. However, they
correspond to thresholds for RRs for complications, rather
than predictions of absolute risk. Furthermore, as with any
diagnostic tests, findings must be interpreted with considera-
tions of likelihood of disease based on the clinical context but
this should not negate the application of a standard
definition for CKD.
Specific concerns:
b) Relationship of CKD criteria to aging
Epidemiologic studies show an increased prevalence of
decreased eGFR and increased ACR in older subjects. There
has been vigorous debate as to whether decreased GFR or
increased ACR in older people represent a disease or ‘‘normal
aging.’’ Numerous studies show pathologic abnormalities
associated with aging, including glomerular sclerosis, tubular
atrophy and vascular sclerosis. The cause for this association
is not clear but has been hypothesized to reflect disparate
processes, such as vascular disease or senescence.37–39
Irrespective of cause, there appears to be increased risk
associated with decreased eGFR or increased ACR in older
people, and for this reason, we consider all individuals with
persistently decreased GFR or increased albuminuria to have
CKD. Comparison of the magnitude of risk to younger
individuals is complicated. As with other CVD risk factors,
absolute risk appears to be higher in older than in younger
individuals, but RR appears to be lower.3-5 Note is also made
that healthy older individuals do not necessarily have
decreased GFR, so that while one may expect some decline,
levels below 60ml/min/1.73m2 in individuals without
comorbidity is the exception.20
c) Isolated decreased GFR without markers of kidney
damage
A variety of clinical circumstances are associated with GFR
o60ml/min/1.73m2 for 43 months in the absence of
known structural alterations. Below are examples of these
conditions and the rationale for considering them as CKD:
K Heart failure, cirrhosis of the liver, and hypothyroidism.
Decreased GFR complicates the management of the
primary disease and patients with these disorders with
decreased GFR have a worse prognosis than those
without decreased GFR. In addition, renal biopsy in
these patients may reveal renal parenchymal lesions.
K Kidney donors. The usual level of GFR in kidney donors
after transplantation is approximately 70% of the pre-
donation level, in the range of 60-90ml/min/1.73m2 in
most donors. However, a minority of donors have GFR
o60ml/min/1.73m2. The prognosis of these donors
24 Kidney International Supplements (2013) 3, 19–62
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compared to those with higher GFR has not been
carefully studied. However, as with decreased GFR due
to recognized kidney diseases, donors with decreased
GFR require closer follow-up for adjustment of drug
doses.
K Malnutrition. The level of GFR is affected by habitual
protein intake.40 Healthy adults with lower protein
intake may have lower mean GFR, but usually do not
have GFR o60ml/min/1.73m2. Older studies of
patients with protein-calorie malnutrition and more
recent studies of subjects with anorexia nervosa have
documented reduced measured GFR that can improve
following restoration of nutritional status. However,
renal biopsies may reveal structural abnormalities in
these conditions and decreased GFR can complicate their
management.
d) Isolated albuminuria without decreased GFR
As described later, transient ACR Z30mg/g (Z3mg/
mmol) can occur in disorders other than CKD. Remission of
albuminuria within 3 months in association with recovery
from these disorders is not defined as CKD. Patients with
persistent albuminuria would be considered to have CKD.
Below are examples of these conditions and the rationale for
considering them as CKD:
K Obesity and metabolic syndrome. Albuminuria can be
associated with obesity and metabolic syndrome, and can
remit during weight loss. The mechanism of albuminuria
in these conditions is not known but renal biopsies may
reveal prominent vascular lesions. Patients with obesity
and metabolic syndrome are at increased risk for
development of diabetes and hypertension. The risk of
persistent albuminuria in this condition has not been
carefully studied.
K Orthostatic (postural) proteinuria.41 Albuminuria may
rarely be observed in the upright but not recumbent
posture in patients with the syndrome of postural
proteinuria. This condition is not associated with an
increased risk of long-term adverse outcomes but a
thorough evaluation is required to exclude other causes
of CKD. Exclusion is generally possible by studying a first
pass early morning urine (EMU) after overnight
recumbency: total protein loss of 41000mg/24 hours is
unlikely to be explained by orthostatic proteinuria.
e) Remission of decreased GFR or markers of kidney
damage
If decreased GFR and markers of kidney damage resolve
while on treatment, the patient would be considered to have
treated CKD, consistent with nomenclature for treated
hypertension, treated diabetes, or treated hypercholesterole-
mia if blood pressure, blood glucose and blood cholesterol
are within normal range while on medications. If resolution
of decreased GFR and markers of kidney damage is sustained
after withdrawal of treatment, the patient would be
considered to have a history of CKD.
f) Kidney disease in the absence of decreased GFR and
markers of kidney damage
A GFR Z60ml/min/1.73m2 may reflect a decline from a
higher value, and an AER of o30mg/24 hours (ACR
o30mg/g or o3mg/mmol) may reflect a rise from a lower
value. Both findings may be associated with a pathologic
process, even in the absence of other markers of kidney
damage. Although such patients do not fulfill the criteria for
CKD, a clinician’s high index of suspicion may warrant
additional diagnostic testing or close follow-up to detect the
onset of CKD.
Pediatric Considerations
In general the definition of CKD in adults applies to children
(birth-18 years) with the following exceptions or allowances:
K the criteria for duration 43 months does not apply to
newborns or infants r3 months of age.
K the criteria of a GFRo60ml/min/1.73m2 does not apply
to children o2 years of age in whom an age appropriate
value should be applied.
K a urinary total protein or albumin excretion rate above
the normal value for age may be substituted for
albuminuria Z30mg/24 hours.
K all electrolyte abnormalities are to be defined in light of
age normative values.
Developmental renal abnormalities account for as many as
30-50% of the children with CKD or ESRD.42 As such many
infants while born with normal SCr for age will in fact meet
the definition of CKD based on structural abnormalities
despite the appearance of a normal GFR and may be classified
as such within the first few days of life.
Normal GFR in newborns is less than 60ml/min/1.73m2,
and it is not until approximately 2 years of age that one
expects to see body surface area (BSA) adjusted GFR values
comparable to those seen in the adult.43,44 The expected
increases in GFR that occur in the first months of life are due
to increases in mean arterial pressure (MAP), decrease in
renal vascular resistance, and redistribution of intrarenal
blood flows to the superficial cortical nephrons in the
newborn and increases in glomerular size and capillary
permeability in the infant.45–48 As such direct application
of the GFR threshold values in the current CKD definition
would not be appropriate in children less than 2 years
of age as their normative maximal values would be below
those of the adult or older child; hence most neonates
and infants would be classified a priori at a decreased GFR
based not on a reduction in GFR from a higher value, but
rather failure of maturity of the kidney.
Numerous references exist for fetal,49 neonatal term,44,48
pre-term,46,50,51 infant, child and adolescent GFR values43,44
and the reader is strongly encouraged to use such references
when comparison to a normative range is required for
approximating the reduction in renal clearance of the
individual child. It should be noted that across these ages
the method of GFR measurement has often varied with the
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majority of such measurements in the neonate (term or
preterm) or infant being derived from urinary collections and
creatinine clearance (CrCl) measurements, whereas the older
children and adolescents are often investigated with exo-
genous markers including inulin, radionuclides, and other
markers such as iohexol or iothalamate.
The most comprehensive list of GFR based on the gold
standard of inulin clearance and stratified by age for
both term and preterm babies and children up to the
age of young adults can be found in Schwartz and Furth’s
review on GFR measurements and estimation in pediatric
CKD.52
Similarly, age relevant normative values should be
utilized when interpreting urinary protein (albumin)
excretions as well as other important urinary and
serum laboratory values. Such values may be found in a
number of pediatric nephrology texts. For neonates
and infants this includes Waters53 and for post-neonate to
young adults, more comprehensive values can be found in
Langlois.54
1.2 STAGING OF CKD
1.2.1: We recommend that CKD is classified based on
cause, GFR category, and albuminuria category
(CGA). (1B)
RATIONALE
This statement is worded in this way because a classification
encompassing cause and severity, as expressed by the level of
GFR and the level of albuminuria, links to risks of adverse
outcomes including mortality and kidney outcomes. These
factors will therefore guide management of CKD and this
recommended classification is consistent with other classifi-
cation systems of disease which are based on the general
domains of cause, duration and severity which provide a
guide to prognosis. We included only kidney measures as
factors in the classification of kidney disease, although we
acknowledge that factors other than kidney measures, such as
level of BP, also affect prognosis in CKD.
This recommended staging with inclusion of two additional
domains represents a revision of the previous CKD guidelines,
which included staging only by level of GFR. Cause of disease is
included because of its fundamental importance in predicting
the outcome of CKD and choice of cause-specific treatments.
With inclusion of cause of kidney disease in the classification,
we considered that it was no longer necessary to retain the use
of the letter ‘‘T’’ to refer to kidney transplant recipients.
Albuminuria is included as an additional expression of severity
of disease not only because it is a marker of the severity of
injury but also because albuminuria itself strongly associates
with progression of kidney disease. Numerous studies have
identified the adverse prognostic implication of albuminuria
irrespective of level of kidney function.
We propose that this classification of CKD by Cause, GFR
and Albuminuria, respectively be referred to as CGA
staging. It can be used to inform the need for specialist
referral, general medical management, and indications for
investigation and therapeutic interventions. It will also be a
tool for the study of the epidemiology, natural history, and
prognosis of CKD.
Pediatric Considerations
The principles inherent in this guideline are fully applicable
to children.
While large scale trials in children relating cause, GFR and
albuminuria or proteinuria are rare, the principles of a
multimodal classification in these three spheres should apply
to children.
To date the only large scale trial utilizing a validated
exogenously measured GFR (iohexol) and urinary protein
excretion in a well-described cohort of children with renal
disease is the Chronic Kidney Disease in Children (CKiD)
trial.55 They have enrolled over 600 children aged 1-16 years
and have described GFR and urinary proteinuria related
outcomes in the areas of neurodevelopment, cognition,
behavior, cardiovascular health and risk, and somatic growth.
They have also collected samples for ongoing and future
genetic study. While these data are sparse in relation to
overall adult numbers, this represents one of the largest
pediatric nephrology trials. The use of true measured GFR,
the quality and completeness of the data, and the long term
longitudinal follow-up will form the basis for the best
evidence-based outcomes in children with CKD for the
foreseeable future. A recent review article by Copelovitch
et al.56 summarizes the major findings of the trial up to the
present time.
1.2.2: Assign cause of CKD based on presence or absence of
systemic disease and the location within the kidney
of observed or presumed pathologic-anatomic
findings. (Not Graded)
RATIONALE
This statement has been included so as to ensure that
clinicians are alerted to the fact that CKD is not a diagnosis in
and of itself, and that the assignment of cause is important
for prognostication and treatment.
The cause of CKD has been traditionally assigned
based on presence or absence of underlying systemic
diseases and location of known or presumed pathologic-
anatomic abnormalities. The distinction between systemic
diseases affecting the kidney and primary kidney diseases
is based on the origin and locus of the disease process.
In primary kidney disease the process arises and is confined
to the kidney whereas in systemic diseases the kidney
is only one victim of a specific process, for example
diabetes mellitus. Certain genetic diseases cross this bound-
ary by affecting different tissues, e.g., adult polycystic
kidney disease. The location of pathologic-anatomic findings
is based on the magnitude of proteinuria, findings from the
urine sediment examination, imaging, and renal pathology.
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Table 4 represents an example of a classification of causes
of kidney diseases based on these two domains.
There is wide geographic variation in the cause of kidney
disease. In developed countries, hypertension and diabetes
are the most frequent causes of CKD, especially in the elderly.
In populations with a high prevalence of diabetes and
hypertension, it can be difficult to distinguish CKD due to
hypertension and diabetes from CKD due to other disorders.
In other countries, other causes of CKD may be as frequent as
hypertension and diabetes (e.g., glomerular disease in East
Asia) or coexist with them. Specialized diagnostic testing,
such as kidney biopsy or invasive imaging studies are
performed only when it is essential to confirm some
diagnoses and the benefits justify the risks and cost. It is
anticipated that cause of disease will not be known with
certainty for many patients with CKD but can be either
inferred or not known.
Pediatric Considerations
The principles inherent in this guideline are fully applicable
to children.
1.2.3: Assign GFR categories as follows [Table 5] (Not
Graded):
RATIONALE
The purpose of this statement is to ensure clarity in
communication. The terms associated with each of the
GFR categories are descriptors which need to be taken in
the context of the individual and are all references to
normal young adults. Note that mildly decreased kidney
function (G2) in the absence of other markers, does not
constitute CKD.
The associations of lower categories of GFR and risks of
metabolic and endocrine complications formed the basis of the
previous stratification into 5 stages. This current classification
further acknowledges the importance of dividing Stage 3 based
on data supporting different outcomes and risk profiles into
categories G3a and G3b (Figure 5). A number of other
concurrent complications are associated with decreased cate-
gories of GFR including infection, impaired cognitive and
physical function, and threats to patient safety.57
Figures 6 and 7 detail the RRs of decreased eGFR
and increasing ACR with future complications, including
mortality and kidney outcomes.30 Even for the group with
the lowest value of albuminuria, the increased RR for all
outcomes is significant for eGFRs below 60ml/min/1.73m2
in the continuous analysis and in the range of 45–59ml/min/
1.73m2 for the categorical analysis.
Pediatric Considerations
In childreno2 years of age with CKD, the GFR categories as
per the adult in Table 5 do not apply; these children should
be categorized as having normal, moderately reduced, or
severely reduced age-adjusted GFR.
No currently agreed upon set of international normative
values or categories exist for GFR in children under the age of
1-2 years. However, the international pediatric nephrology
community has embraced the adult CKD staging system as
per the 2002 KDOQI guidelines in children over the age of
2 years, as suggested by Hogg et al.43
Table 4 | Classification* of CKD based on presence or absence of systemic disease and location within the kidney of pathologic-
anatomic findings
Examples of systemic diseases
affecting the kidney
Examples of primary kidney diseases (absence of
systemic diseases affecting the kidney)
Glomerular diseases Diabetes, systemic autoimmune diseases, systemic
infections, drugs, neoplasia (including amyloidosis)
Diffuse, focal or crescentic proliferative GN; focal and
segmental glomerulosclerosis, membranous nephropathy,
minimal change disease
Tubulointerstitial
diseases
Systemic infections, autoimmune, sarcoidosis,
drugs, urate, environmental toxins
(lead, aristolochic acid), neoplasia (myeloma)
Urinary-tract infections, stones, obstruction
Vascular diseases Atherosclerosis, hypertension, ischemia, cholesterol
emboli, systemic vasculitis, thrombotic
microangiopathy, systemic sclerosis
ANCA-associated renal limited vasculitis, fibromuscular
dysplasia
Cystic and congenital
diseases
Polycystic kidney disease, Alport syndrome,
Fabry disease
Renal dysplasia, medullary cystic disease, podocytopathies
Abbreviations: ANCA, antineutrophil cytoplasmic antibody; CKD, chronic kidney disease, GN, glomerulonephritis
Genetic diseases are not considered separately because some diseases in each category are now recognized as having genetic determinants.
*Note that there are many different ways in which to classify CKD. This method of separating systemic diseases and primary kidney diseases is only one, proposed by the
Work Group, to aid in the conceptual approach.
Table 5 | GFR categories in CKD
GFR category GFR (ml/min/1.73m2) Terms
G1 Z90 Normal or high
G2 60–89 Mildly decreased*
G3a 45–59 Mildly to moderately decreased
G3b 30–44 Moderately to severely decreased
G4 15–29 Severely decreased
G5 o15 Kidney failure
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
*Relative to young adult level
In the absence of evidence of kidney damage, neither GFR category G1 nor G2 fulfill
the criteria for CKD.
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As indicated in Pediatric Considerations for Guideline 1.1,
the normative GFR values for children less than 2 years vary
quite widely by both age and method of measurement. More
importantly these values are expected to increase in a non-
linear fashion over the first 2 years of life with significant
changes seen in the first few months post-birth and no
current evidence of presence of comorbid conditions at any
given level of measured or estimated GFR in this population.
As such, specific categorization of G1-5 as suggested in this
Recommendation would seem not be of value, and might be
misleading if applied to a child less than 2 years of age.
With this in mind, it is suggested that based on the chosen
method of GFR measurement or comparison for the
individual (i.e., CrCl, radioactive or cold exogenous serum
markers, or estimating formula), that one should attempt to
classify the child under the age of 2 years as having normal,
moderate or severe reductions in GFR based on the
normative range and standard deviations (SDs) for the
method. No evidence exists for this recommendation but
recognition that values of GFR more than 1 SD below the
mean would seem likely to raise concern of the clinician and
foster the need for closer monitoring. For drug dosing
adjustments it is suggested that those children with GFRs
below the mean by 41 but o2 SD be classified as having a
moderate reduction in GFR whereas those more than 2 SD
below the mean for the method be classified as having a
severe reduction in GFR.
1.2.4: Assign albuminuria* categories as follows [Table 6]
(Not Graded):
*note that where albuminuria measurement is
not available, urine reagent strip results can be
substituted (Table 7)
RATIONALE
The purpose of this statement is to ensure communication
and to reflect that albuminuria category is an important
predictor of outcomes. The association of high levels of
proteinuria with signs and symptoms of nephrotic syndrome
is well known. The detection and evaluation of lesser
quantities of proteinuria have gained additional significance
as multiple studies have demonstrated its diagnostic,
pathogenic, and prognostic importance. There is a contin-
uous risk associated with albuminuria but the use of a simple
categorical approach was selected to simplify the concept for
Figure 5 |Age-standardized rates of death from any cause
(panel a), cardiovascular events (panel b), and hospitalization
(panel c), according to the eGFR among 1,120,295 ambulatory
adults. eGFR, estimated glomerular filtration rate. From N Engl J
Med, Go AS, Chertow GM, Fan D, et al.58 Chronic kidney disease and
the risks of death, cardiovascular events, and hospitalization, 351:
1296-1305. Copyright & (2004) Massachusetts Medical Society.
Reprinted with permission from Massachusetts Medical Society;
accessed http://www.nejm.org/doi/pdf/10.1056/NEJMoa041031
Table 6 | Albuminuria categories in CKD
AER
ACR (approximate
equivalent)
Category
(mg/24 hours) (mg/mmol) (mg/g)
Terms
A1 o30 o3 o30 Normal to mildly
increased
A2 30-300 3-30 30-300 Moderately increased*
A3 4300 430 4300 Severely increased**
Abbreviations: AER, albumin excretion rate; ACR, albumin-to-creatinine ratio;
CKD, chronic kidney disease.
*Relative to young adult level.
**Including nephrotic syndrome (albumin excretion usually 42200mg/24 hours
[ACR 42220mg/g; 4220mg/mmol]).
28 Kidney International Supplements (2013) 3, 19–62
chapte r 1
clinical practice. Several groups had suggested sub-
dividing one or more GFR categories based on albuminuria
category.
For the detection of diabetic nephropathy some guidelines
recommend the use of different ACR thresholds for males
and females (425mg/g [42.5mg/mmol] and 435mg/g
[43.5mg/mmol], respectively) to take into account varia-
tions in creatinine excretion. A single threshold is used in
North America (30mg/g or 3.4mg/mmol). Earlier KDIGO
guidance was reluctant to adopt gender-specific thresholds
due to greater complexity, uncertainty about assay precision,
and effects of race, ethnicity, diet and measures of body size
on creatinine and this stance is maintained here. For
simplicity, and to reflect the fact that it is an approximation,
3.4mg/mmol as the current guideline threshold has been
rounded to 3.0mg/mmol.
There is a graded increase in risk for higher albuminuria
categories, at all GFR categories, without any clear threshold
value. Even for subjects with GFR 460ml/min/1.73m2,
the increased RR is statistically significant for urine
ACR Z30mg/g (Z3mg/mmol) for mortality and kidney
outcomes (Figures 6 and 7). The predictive ability of
albuminuria at all categories of GFR supports the suggestion
to add albuminuria categories to all GFR categories. Since the
relationship with albuminuria is continuous, the selection of
the number of categories and the cutoff values appears
arbitrary. The Work Group has recommended the classifica-
tion of albuminuria into only 3 categories, based on practical
considerations, but recognized that further subdivisions
within the category of o30mg/24 hours (ACRo30mg/g
or o3mg/mmol) may be useful for risk stratification,
and that subdivisions within the category of 4300mg/
24 hours (ACR4300mg/g or 430mg/mmol) may be
useful for diagnosis and management. Specifically there
is a recognition that nephrotic range proteinuria
(AER42200mg/24 hours [ACR42200mg/g;4220mg/
mmol]; PER43000mg/24 hours [43000mg/g;4300mg/
mmol]) confers unique additional risks and is usually
associated with specific conditions (such as GN). As these
are relatively rare in general practices, the simplicity of the
AER categorization was preferred. Table 7 shows the
approximate relationships of categories of AER to other
measures of albuminuria and proteinuria.
Implications for Clinical Practice and Public Policy
Data from around the world suggest that CKD prevalence is
between 10-16% but information concerning population
prevalence by category of GFR and ACR is scant. Figure 8
shows the proportion of adults in the US by categories
of GFR and albuminuria.19 While CKD is common, few
individuals have severely reduced GFR or kidney failure or
severely increased albuminuria.
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Figure 6 | Summary of continuous meta-analysis (adjusted RRs) for general population cohorts with ACR. Mortality is reported for
general population cohorts assessing albuminuria as urine ACR. Kidney outcomes are reported for general population cohorts assessing
albuminuria as either urine ACR or reagent strip. eGFR is expressed as a continuous variable. The three lines represent urine ACR of o30,
30-299 and Z300mg/g (o3, 3-29, and Z30mg/mmol, respectively) or reagent strip negative and trace, 1þ positive, Z2þ positive. All
results are adjusted for covariates and compared to reference point of eGFR of 95ml/min/1.73m2 and ACR ofo30mg/g (o3mg/mmol) or
reagent strip negative (diamond). Each point represents the pooled RR from a meta-analysis. Solid circles indicate statistical significance
compared to the reference point (P o0.05); triangles indicate non-significance. Red arrows indicate eGFR of 60ml/min/1.73m2, threshold
value of eGFR for the current definition of CKD. ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease; eGFR, estimated glomerular
filtration rate; HR, hazard ratio; OR, odds ratio, RR, relative risk. Reprinted with permission from Macmillan Publishers Ltd: Kidney
International. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO
controversies conference report. Kidney Int 2011; 80: 17-2830; accessed http://www.nature.com/ki/journal/v80/n1/full/ki2010483a.html
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The classification of kidney disease by cause, category of
GFR and category of albuminuria does not conform to the
International Classification of Diseases (ICD) maintained by
the World Health Organization (WHO). Currently the WHO
is developing an update (ICD 11). It will be important to
communicate and coordinate efforts with the kidney disease
subgroup for ICD 11. However, the proposed current
classification does address the need in clinical practice to
acknowledge the multiple dimensions and variables by which
individual patients are assessed. Table 8 gives examples of the
use of CGA nomenclature.
Definition of GFR categories have been deliberately based
upon the concept of ‘‘true’’ GFR, whereas clinical practice
and research has predominantly used creatinine-based
estimates of GFR. The belief of the Work Group is that the
non-GFR determinants of creatinine and the imprecision of
creatinine-based GFR estimates have resulted in the absence
of strong dose-dependent association of eGFR with clinical
outcomes in the GFR range of 460ml/min/1.73m2. The
Work Group felt confident that GFR levels of Z90ml/min/
1.73m2 portend better prognosis than GFR levels 60-89ml/
min/1.73m2, if they could be estimated accurately. Therefore,
the GFR categories include separate G1 (Z90ml/min/
1.73m2) and G2 (60-89ml/min/1.73m2) designations despite
limited data from creatinine-based estimates that prognosis
differs between these two categories. It is also an acknowl-
edgement that the degree of precision of some of our
measurements may not be able to differentiate between these
2 categories reliably. As described later, studies that have used
cystatin C have found gradients in prognosis at eGFR levels
above 60ml/min/1.73m2, which supports the belief of the
committee that separating these 2 GFR categories is
appropriate for CKD classification.
Albuminuria categories are ‘‘wide’’ with respect to risk,
with significant gradients within each category. The decision
to propose only 3 categories is based on the perceived need
for simplification in clinical practice. In specialized clinical
nephrology centers, A3 (4300mg/g or 430mg/mmol) is
often more precisely assessed and divided into additional
categories. For example, nephrotic range proteinuria is
defined as PER43500mg/24 hours or PCR (protein-
to-creatinine ratio) 43500mg/g [4350mg/mmol] which
is approximately equivalent to AER42200mg/24 hours
or ACR42200mg/g [220mg/mmol]. It is clearly recognized
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Figure 7 | Summary of categorical meta-analysis (adjusted RRs) for general population cohorts with ACR. Mortality is reported for
general population cohorts assessing albuminuria as urine ACR. Kidney outcomes are reported for general population cohorts assessing
albuminuria as either urine ACR or reagent strip. eGFR and albuminuria are expressed as categorical variables. All results are adjusted for
covariates and compared to the reference cell (Ref). Each cell represents a pooled RR from a meta-analysis; bold numbers indicate statistical
significance at P o0.05. Incidence rates per 1000 person-years for the reference cells are 7.0 for all-cause mortality, 4.5 for CVD mortality,
0.04 for kidney failure, 0.98 for AKI, and 2.02 for CKD progression. Colors reflect the ranking of adjusted RR. The point estimates for each cell
were ranked from 1 to 28 (the lowest RR having rank number 1, and the highest number 28). The categories with a rank number 1-8 are
green, rank numbers 9-14 are yellow, the rank numbers 15-21 are orange and the rank numbers 22-28 are colored red. (For the outcome of
CKD progression, two cells with RRo1.0 are also green, leaving fewer cells as yellow, orange and red). ACR, albumin-to-creatinine ratio; AKI,
acute kidney injury; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage
renal disease; RR, relative risk. Reprinted with permission from Macmillan Publishers Ltd: Kidney International. Levey AS, de Jong PE, Coresh J,
et al.30 The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int 2011; 80:
17-28; accessed http://www.nature.com/ki/journal/v80/n1/full/ki2010483a.html
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that these very high levels of proteinuria carry a different
risk than lower values within the same category. Further
differentiation after quantification and evaluation would
inform treatment decisions for an individual patient. These
categories serve as an initial assessment and prognostication
tool; further classification is appropriate for specific circum-
stances and is not limited by the initial classification into only
3 categories.
Note that the term ‘microalbuminuria’ is not used and is
discouraged in this classification system. This will require a
formal education program and review of existing guidelines
in other disciplines so that consistency of terminology and
Table 7 | Relationship among categories for albuminuria and proteinuria
Categories
Measure Normal to mildly increased (A1) Moderately increased (A2) Severely increased (A3)
AER (mg/24 hours) o30 30–300 4300
PER (mg/24 hours) o150 150–500 4500
ACR
(mg/mmol) o3 3–30 430
(mg/g) o30 30–300 4300
PCR
(mg/mmol) o15 15–50 450
(mg/g) o150 150–500 4500
Protein reagent strip Negative to trace Trace to + + or greater
Abbreviations: ACR, albumin-to-creatinine ratio; AER, albumin excretion rate; PCR, protein-to-creatinine ratio; PER, protein excretion rate.
Albuminuria and proteinuria can be measured using excretion rates in timed urine collections, ratio of concentrations to creatinine concentration in spot urine samples, and
using reagent strips in spot urine samples. Relationships among measurement methods within a category are not exact. For example, the relationships between AER and ACR
and between PER and PCR are based on the assumption that average creatinine excretion rate is approximately 1.0 g/d or 10mmol/d. The conversions are rounded for
pragmatic reasons. (For an exact conversion from mg/g of creatinine to mg/mmol of creatinine, multiply by 0.113.) Creatinine excretion varies with age, sex, race and diet;
therefore the relationship among these categories is approximate only. ACR o10mg/g (o1mg/mmol) is considered normal; ACR 10–30mg/g (1-3mg/mmol) is considered
‘‘high normal.’’ ACR 42200mg/g (4220mg/mmol) is considered ‘‘nephrotic range.’’ The relationship between urine reagent strip results and other measures depends on
urine concentration.
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understanding of the changes are universal (see Recommen-
dation 1.4.4.2.1).
Pediatric Considerations
This statement would need to be altered for application in
pediatric practice in the following way. In children with CKD
any expression of abnormal urinary protein excretion,
irrespective of the marker:
K must account for variation in that measurement as seen
across age, sex, puberty and or body size (height, weight,
body mass index [BMI]).
K should account for the possibility of tubular versus
glomerular proteinuria dominance dependent on the
underlying disease.
K may utilize proteinuria in place of albuminuria.
There is no set standard encompassing all children with
respect to the normal range of urinary protein (or albumin)
excretion. Values vary across age, sex, race, pubertal status,
the presence of obesity (high BMI) and may be modified by
exercise, fever, and posture.60–63
In general, neonates and young infants/ children are both
expected and allowed to have higher urinary losses of both
glomerular and tubular proteinuria due to lack of maturation
in the proximal tubular reabsorption of proteins. The rough
equivalences for ACR and PCR quoted in the pediatric
literature are similar, but not identical to those quoted in the
adult literature. Normal ranges vary but at least one reference
suggests as much as 6-8mg/m2/hr or 4240mg/m2/day of
proteinuria as being acceptable at o6 months of age;64
normal ranges for urinary albumin losses are not known at
this age.
The normal range of protein excretion for children 6-24
months of age in a 24-hour urine collection is quoted as
being o4mg/m2/hr (o150mg/m2/day), whereas the first
morning spot urine protein sample is said to be normal at
levels of o500mg/g creatinine (o50mg/mmol). In children
older than 24 months these values are o4mg/m2/hr
(o150mg/m2/day) for the 24-hour collection and PCR
o200mg/g creatinine (o20mg/mmol) in the first morning
urine sample, or a first morning urine ACR o30mg/g
(o3mg/mmol).43,65
At all ages, total urinary protein excretion 440mg/m2/hr
(43 grams/1.73m2/day) is considered to represent ‘nephrotic
range’ loss of protein, with intermediate values, i.e.,
4-40mg/m2/hr or its equivalent representing abnormal but
‘non-nephrotic’ losses.43,65
Children older than 24 months of age are expected to
achieve normal (‘adult’) urinary protein values with the
caveat of an exaggerated postural loss of glomerular proteins
(albumin) as can commonly be seen in the 2-5% of the
adolescent population (i.e., orthostatic proteinuria).62
Based on National Health and Nutrition Examination
Survey III (NHANES III) data from just under 6000 healthy
6-19 year old children using either immunonephelometry or
radioimmunoassay, the definition of urinary albumin excre-
tion was determined to be 30-300mg/24 h collection;
20-200mg/min in an overnight collection and 30-300mg/g
creatinine (3-30mg/mmol) in a first morning urine sample.66
Of note, to date the majority of studies that have
examined the effects of urinary protein losses or therapeutic
interventions have concentrated on so-called total protein
excretion or random or first morning PCRs. The utility
of measuring the albumin only fraction, and in particular
Table 8 | CGA staging of CKD: examples of nomenclature and comments
Cause
GFR
category
Albuminuria
category Criterion for CKD Comment
Diabetic kidney disease G5 A3 Decreased GFR, Albuminuria Most common patient in the low clearance clinic
Idiopathic focal sclerosis G2 A3 Albuminuria Common cause of nephrotic syndrome in childhood
Kidney transplant
recipient
G2 A1 History of kidney transplantation Best outcome after kidney transplantation
Polycystic kidney disease G2 A1 Imaging abnormality Most common disease caused by a mutation in a single
gene
Vesicoureteral reflex G1 A1 Imaging abnormality Common condition in children
Distal renal tubular
acidosis
G1 A1 Electrolyte abnormalities Rare genetic disorder
Hypertensive kidney
disease
G4 A2 Decreased GFR and albuminuria Usually due to long-standing poorly controlled
hypertension, likely to include patients with genetic
predisposition- more common in blacks- who should
be referred to nephrologist because of severely
decreased GFR
CKD presumed due to
diabetes and hypertension
G4 A1 Decreased GFR Should be referred to nephrologist because of severely
decreased GFR
CKD presumed due to
diabetes and hypertension
G2 A3 Albuminuria Should be referred to nephrologist because of
albuminuria
CKD presumed due to
diabetes and hypertension
G3a A1 Decreased GFR Very common, may not require referral to nephrologist
CKD cause unknown G3a A1 Decreased GFR May be the same patient as above
Abbreviations: CGA, Cause, GFR category and albuminuria category; CKD, chronic kidney disease; GFR, glomerular filtration rate.
Note: Patients above the thick horizontal line are likely to be encountered in nephrology practice. Patients below the thick horizontal line are likely to be encountered in
primary care practice and in nephrology practice.
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quantitating this at the lower level of detection, i.e.,
o30mg/g (o3mg/mmol) creatinine, is only now being
investigated in more detail in large pediatric studies. As such
it should be recognized that in children the quantification of
total protein, as compared to the albumin only fraction, may
be the preferred method for assigning risk as it relates to
the presence of urinary protein loss.
In summary, for children older than 2 years of age the
assignment of ‘proteinuria’ categories can be used as per the
adult guidelines with the understanding that modification to
the upper limit of expected values may be necessary in
consideration of the factors outlined above. Although there is
a preference for reporting albumin values, currently many
clinicians still categorize these children based on total protein
and in the child o2 years of age or the adolescent with
demonstrable orthostatic proteinuria, the current albumin-
uria categories are unlikely to apply.
1.3: PREDICTING PROGNOSIS OF CKD
1.3.1: In predicting risk for outcome of CKD, identify
the following variables: 1) cause of CKD; 2) GFR
category; 3) albuminuria category; 4) other risk
factors and comorbid conditions. (Not Graded)
1.3.2: In people with CKD, use estimated risk of
concurrent complications and future outcomes
to guide decisions for testing and treatment for
CKD complications (Figure 9). (Not Graded)
1.3.3: In populations with CKD, group GFR and
albuminuria categories with similar relative risk
for CKD outcomes into risk categories (Figure 9).
(Not Graded)
RATIONALE
These statements are worded in this way because for all CKD
complications, prognosis will vary depending on: 1) cause; 2)
GFR; 3) degree of albuminuria; and 4) other comorbid
conditions. The relative strength of each of these factors will
vary for each complication or outcome of interest. Risk for
kidney disease end points, such as kidney failure and AKI, is
predominately driven by an individual patient’s clinical
diagnosis, GFR, and the degree of albuminuria or other
markers of kidney damage and injury. For CVD, risk will be
determined by history of CVD and traditional and non-
traditional CVD risk factors. For other conditions, the risk
will be determined by risk factors specific for those
conditions. For all conditions, the cause of CKD, GFR
category, and albuminuria category will still have important
influence as ‘‘risk multipliers,’’ but will have smaller overall
influence on disease prediction than risk factors specific for
the condition. All these conditions have an impact on life
expectancy and quality of life (QOL) and contribute
substantially to predicting the prognosis of CKD. CKD is
associated with numerous complications directly or indirectly
related to the cause of CKD, decreased GFR, or albuminuria
(Table 9).
The risk associations of GFR and albuminuria categories
appear to be largely independent of one another. Therefore,
neither the category of GFR nor the category of albuminuria
alone can fully capture prognosis for a patient with CKD. The
magnitude and gradients of risk across categories of GFR and
albuminuria will likely differ for each specific adverse event.
This heterogeneity across the GFR and ACR grids in RRs for
different outcomes makes it impractical to have a simple
hierarchical staging of prognosis across all cells. Thus, the
staging using CGA should be descriptive, but encompassing
the ordered categories of GFR and ACR (Figure 9).
The CGA staging system proposed in this guideline
provides a framework for future recommendations on CKD
clinical management. At present, much of the evidence on
clinical decision making in CKD is based solely on GFR. This
recommendation serves to highlight the multidimensional
Table 9 | Prognosis of CKD: Relationship of outcomes and strength of relationship to Cause (C), GFR (G), Albuminuria (A) and
other measures*67,68
Kidney measures
Outcomes Cause GFR Albuminuria Other measures
Kidney outcomes
GFR decline +++ + +++ High BP, male sex, black race, younger age
Albuminuria rise +++ + +++ High BP, diabetes
AKI + +++ + Older age
Chronic kidney failure (GFR o15ml/min/1.73m2; category G5) +++ +++ + Younger age
Complications (current and future)
Drug toxicity + +++ + Drug exposure, liver disease
Endocrine and metabolic + +++ + Various
CVD and mortality ++ +++ +++ Older age, history of CVD, CVD risk factors
Others (infection, cognitive impairment, frailty, etc) ++ ++ ++ Older age, comorbid conditions
Abbreviations: AKI, acute kidney injury; BP, blood pressure; CVD, cardiovascular disease; GFR, glomerular filtration rate.
Plus signs indicate the strength of the risk relationship between the CKD characteristic and the outcome: +, somewhat associated; ++, moderately associated; +++, strongly
associated.
*Note that the + designations refer to strength of relationship not strength of evidence to support, and are based on consensus overview by the Work Group members.
Adapted with permission from Uhlig K, Levey AS.68 Developing guidelines for chronic kidney disease: we should include all of the outcomes. Ann Intern Med 2012; 156(8):
599-601.
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aspect of CKD so as to ensure appropriate consideration of
the complexity of the condition.
Evidence Base
The evidence base from which these statements are
derived includes large observational cohort studies from
diverse populations. For some outcomes, including
mortality, CVD, and kidney disease progression, meta-
analyses have summarized the risk associations. For out-
comes that occur predominately in older adults (e.g.,
dementia, fracture), the evidence is largely limited to cohorts
of older people.
Extensive work by the CKD Prognosis Consortium has
defined the RRs across GFR and albuminuria categories for
several important outcomes, including all-cause mortality,
CVD, and kidney failure (Figures 6 and 7). Risk increases
incrementally in both directions - down the GFR categories
and across the albuminuria categories. Levels of risk can be
identified and grouped into categories, but they may differ
somewhat for each outcome. Additional research is needed
to map these GFR and albuminuria categories and cause
of kidney disease to other important outcomes of CKD
(Table 9).
International Relevance
The above statements appear to be robust when applied in
North America, Europe and Asia.30 Thus, it appears for all
methods used to determine GFR and to detect albuminuria,
the use of the 3 parameters (cause, category of GFR and
category of albuminuria) influences prognosis irrespective of
ethnicity or country of origin.
Implications for Clinical Practice and Public Policy
Providers must incorporate cause of kidney disease, GFR
category and albuminuria category in order to better develop
an accurate assessment of an individual’s prognosis related to
CKD. Many providers who are not nephrologists will need
guidance in the local methods for requesting and interpreting
a urine albumin assessment and an eGFR. Use of risk scores
which are being developed and refined is advised.
Public policy and estimates of total burden of illness in a
community need to take into account the incidence and
prevalence of specific conditions (such as diabetes and
congestive heart failure). In addition, knowledge of distribu-
tion of levels of eGFR and ACR may be valuable for resource
planning. Community or health-system based interventions
to reduce the incidence of kidney failure in populations
should be targeted and prioritized based on these 3 criteria.
The primary impact on clinical practice will relate to
kidney-specific complications of CKD and referral patterns to
help prevent and manage them. Decisions related to screen-
ing and monitoring CKD disorders will be informed and
guided by the CGA system. At present, this evidence for
issues such as management of anemia, CKD bone and
mineral disorders, and acid-base disorders has not been
organized and presented in this way.
Decisions on screening and referral strategies have major
impact on the costs and quality of health-care. The value of
Prognosis of CKD by GFR
and Albuminuria Categories:
KDIGO 2012
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G3b 30-44
G4 Severely decreased 15-29
G5 Kidney failure <15
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Moderately to
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Figure 9 |Prognosis of CKD by GFR and albuminuria category. Green, low risk (if no other markers of kidney disease, no CKD); Yellow,
moderately increased risk; Orange, high risk; Red, very high risk. CKD, chronic kidney disease; GFR, glomerular filtration rate; KDIGO, Kidney
Disease: Improving Global Outcomes. Modified with permission from Macmillan Publishers Ltd: Kidney International. Levey AS, de Jong PE,
Coresh J, et al.30 The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int
2011; 80: 17-28; accessed http://www.nature.com/ki/journal/v80/n1/full/ki2010483a.html
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this revised system of classification is that it will allow the
evaluation of different referral patterns and the impact of
treatment strategies in those with diverse CGA assignment. In
this way, we will develop additional evidence which will
inform practice patterns. These will necessarily be developed
locally and reflect the values and economic realities of each
health-care system.
Areas of Controversy, Confusion, or Non-consensus and
Clarification of Issues and Key points
Current clinical practice has not overtly incorporated these 3
variables into all decision making activities. The utility of the
system will need to be vetted by those referring and those to
whom patients are referred. The overt description of the 3
dimensions of diagnosis and staging of kidney disease which
include the cause, the category of GFR and the category of
albuminuria, should help to inform referral and treatment
patterns of large groups of individuals. Risk calculators for
specific events are under development.
K The CGA classification system will be useful for
quantifying risk for specific outcomes of CKD but its
utility has not been fully assessed in clinical practice and
research studies.
K Additional evidence is required before decisions on screen-
ing, monitoring, and referral patterns can be fully informed.
Pediatric Considerations
For Recommendation 1.3.1 the rationale and principles
behind this statement would apply to pediatrics though the
data are not available.
Unlike in adults, the knowledge of risk of progression or
outcomes of CKD is less robust in children, with the majority
of such information gleaned from either registry datasets or
longitudinal trials. In a 2008 report of a select group of patients
enrolled by various North American pediatric nephrology
centers in the North American Pediatric Renal Trials and
Collaborative Studies (NAPRTCS) registry, 46% of nearly 7100
cases had reached a final ‘end point’ with 86% progressing to
ESRD over their time in the registry.69 Data from the
prospective registry and population-based Italian Pediatric
Registry of Chronic Renal Failure (ItalKid) study demonstrated
a risk of progression to ESRD of B68% by age 20 years.70
Cause of CKD. Specific information related to rate of
progression for all pediatric causes of CKD is not easily
available. However data from the prospective longitudinal
CKiD trial has demonstrated a more rapid decline in renal
function in children whose underlying cause of CKD is
classified as glomerular with an annualized rate of change
in iohexol GFR of 10.5% as compared to those with
a non-glomerular cause in whom the annualized rate of
change is only 3.9%.71 In terms of absolute rates of
change in measured iohexol GFR this translated, in a
separate analysis from the same dataset, into a median
change of GFR of 4.3ml/min/1.73m2 versus 1.5ml/min/
1.73m2 in the glomerular versus non-glomerular groups,
respectively.72 This paper also provides the only current
individual disease-specific estimate of annual decline in a
pediatric population. Table 10 illustrates that the median
values for annualized change in GFR for various diagnosis
categories.
Similarly, a randomized controlled trial (RCT) from
Europe73 examining the effects of diet on rate of progression
demonstrated a statistically significant difference in CrCl
between their glomerular and non-glomerular cohorts at 2
years of follow-up; with the mean decline [SD] in the
glomerular group being 10.7 [11.3] versus 8.4 [13.5] ml/
min/1.73m2 in the non-glomerular patients (P ¼ 0.048).
GFR category. It is also well recognized that there is an
inverse relationship between the rates of progression of
kidney disease to the level of kidney function present at that
presentation with more rapid decline seen in patients with
lower initial levels of GFR. Staples et al.74 in their retro-
spective review of the NAPRTCS CKD database involving
nearly 4200 children registered with GFR categories G2-G4
(GFR 15-89ml/min/1.73m2) demonstrated significantly
higher rates of progression, defined by progression to GFR
category G5 (GFR o15ml/min/1.73m2) or initiation of
dialysis or transplant, for children in GFR categories G3a-G4
(GFR 15–59ml/min/1.73m2) as compared to those with
CKD and GFR category G2 (GFR 60–89ml/min/1.73m2) at
time of enrollment: hazard ratio (HR) of GFR categories 3a
and 3b (GFR 30–59ml/min/1.73m2) (GFR category 2 (GFR
60–89ml/min/1.73m2) ¼ 1.00 as referent): 2.00; 95%
confidence interval (CI) 1.64-2.42; Po0.0001 and HR of
GFR category 4 (GFR 15–29ml/min/1.73m2): 6.68; 95% CI
5.46-8.18; Po0.0001.
Albuminuria (proteinuria). Several studies have also de-
monstrated the effect of proteinuria on rate of progression of
CKD in children. Using registry data, and in non-glomerular
conditions the ItalKids trial75 demonstrated a significantly
slower decline in CrCl in patients with baseline PCRs of
o200mg/g (20mg/mmol) and 200–900mg/g (20–90mg/
mmol) when compared to those patients with a PCR of
4900mg/g (490mg/mmol); slope þ 0.16±3.64 and
Table 10 | Annual percentage change in GFR across diagnosis
categories
Disease
Annualized percentage change
[number of patients]
Focal and segmental
glomerulosclerosis
-13.3% [N=34]
Hemolytic uremic syndrome -1.3% [N=27]
Other glomerular -15.5% [N=51]
Obstructive uropathy -4.6% [N=109]
Aplastic/hypoplastic/dysplastic
kidneys
-3.3% [N=96]
Reflux nephropathy -3.8% [N=82]
Autosomal recessive polycystic
kidney disease
-4.4% [N=18]
Other non-glomerular -2.5% [N=119]
Abbreviation: GFR, glomerular filtration rate.
Data from Furth et al.72
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0.54±3.67 versus 3.61 ±5.47 (P o0.0001). This
translated to higher rates of kidney survival over 5 years in
the lower proteinuria groups, 96.7% and 94.1% versus
44.9%, (P o0.01). Multivariate analysis confirmed that the
baseline PCR correlated with a more rapid decline in CrCl for
any given level of baseline function.
In a prospective multicenter randomized trial of protein
intake on rates of progression in children aged 2-18 years of
age, Wingen et al. employed the Schwartz equation to
estimate CrCl and demonstrated that baseline proteinuria in
multivariate analysis was the most important independent
predictor of change in CrCl. The authors reported a partial
R2 of 0.259 at 2 years follow-up and similar results were
found after the study was extended for a third year.73 Life-
table analysis in this study also suggested a cutoff value of
50mg/kg/day of proteinuria as a strong predictor of time to a
decline in CrCl410ml/min/1.73m2 and found a risk ratio of
4.01 (95% CI 2.23–7.25; Po0.001).
Finally Wong et al.76 used cross sectional data from the
prospective longitudinal CKiD trial to demonstrate that even
after controlling for age, race, BMI, cause of CKD and use of
RAAS antagonists they could expect an average decline in
measured GFR of 10% for every increase in urinary PCR of
14% (95% CI 10-18%).
Other risk factors and comorbid conditions. Many other
risk factors and comorbid conditions have also been
associated with greater risk of progression of CKD in adults
but only a few of these have been convincingly proven in
children due to lack of pediatric prospective trials.
Hypertension is by far the best studied of these risk factors
in children, with clear evidence from multiple sources to
document the value of aggressive BP control on slowing the
rate of progression of CKD. Wingen et al.73 demonstrated the
importance of systolic BP in rate of progression in both
univariate and multivariate models. In this study Cox
proportional hazards analysis demonstrated a systolic BP
4120mm Hg was an independent risk for decline in CrCl by
410ml/min/1.73m2; risk ratio was 3.1 (95% CI 1.74-5.53;
Po0.001).
The most important prospective pediatric BP trial to date,
the Effect of Strict Blood Pressure Control and ACE-
Inhibition on Progression of Chronic Renal Failure in
Pediatric Patients (ESCAPE) study, used ambulatory BP
monitoring (ABPM) and a fixed dose of ramipril plus
additional antihypertensive agents that do not target the
RAAS to assess (as primary outcomes) the time to decline of
50% in GFR or development of ESRD. Their results
demonstrated a 35% reduction in the risk of achieving the
primary end point in the more intensely treated BP: HR 0.65;
95% CI 0.44-0.94; P¼ 0.02. Further sub-analysis as reported
in the KDIGO BP Guideline10 demonstrated that kidney
survival was 66.1% at 5 year follow-up in patients with
systolic BPo90th percentile for age whereas it was 41% in the
patients who did not achieve this level of reduction
(P¼ 0.0002); similar numbers were seen if diastolic BP was
the metric considered.
The issue of puberty and its effect on rate of progression
has recently been addressed by the ItalKids investigators.77
While the methodology of their analysis is less than ideal as
they did not determine actual Tanner stages in the majority of
their cohort and used estimated rather than measured GFR,
they do appear to demonstrate a decrease in kidney survival
probability beginning around 10.9 years in girls and 11.6
years in boys with CKD. Of note, the rate of decline in kidney
survival, using these age points as ‘inflection’ or break points,
is dramatically increased in both sexes based on their
evidence provided in graphical form, although more precise
analyses are not possible from the data provided.
As in adults, other factors for consideration and value in
monitoring in children with respect to risk of progression
include obesity, metabolic acidosis, anemia, calcium-phos-
phate metabolism, chronic inflammation, diabetes, hyperur-
icemia, dyslipidemia, and smoking.
The most comprehensive review of many of these factors
in children comes from a retrospective study of the
NAPRTCS CKD database. Staples et al.74 demonstrated that
in a multivariate analysis of nearly 4200 children registered
with CKD and GFR categories G2-G4 (GFR 15–89ml/min/
1.73m2), the following factors were significantly associated
with the risk of CKD progression (defined by progression to
GFR category G5 (GFRo15ml/min/1.73m2) or initiation of
dialysis or transplant): age; primary disease; GFR category;
registration year; hypertension; corrected calcium, phos-
phorus, albumin, and hematocrit; and as proxies, the use of
medications for anemia and short stature. The ability of this
paper to prove causation or value in treating any of these
conditions in hopes of delaying CKD progression is limited
by its retrospective nature, and the fact that data were
accrued from a voluntary registry.
There is optimism that prospective data from current large
pediatric trials such as CKiD55 and the European Cardiovas-
cular Comorbidity in Children with CKD (4C) trial78 will
lead to a better understanding of how risk factors may be
influencing the rate of progression of CKD in children.
For Recommendation 1.3.2 the rationale and principles
behind this statement would apply to pediatrics, though the
data are not available. Insufficient evidence currently exists
with respect to the predictive value of prevalent risk factors to
guide future decisions for testing or treatment for CKD
complications in an individual child.
It is hoped that well powered, prospective trials with
adequate follow-up, such as the CKiD55 and European 4C78
trials, will gather sufficient numbers of patients, comorbid-
ities, and outcomes to allow for predictive models to be built
in pediatric CKD that incorporate traditional and non-
traditional cardiac risk factors including dyslipidemia and
hypertension, proteinuria (albuminuria), specific disease-
related issues (e.g., diabetes, tubulopathy), prematurity, and
birth weight.
For Recommendation 1.3.3 the rationale and principles
behind this statement would apply to pediatrics, though the
data are not available. Current evidence and a paucity of
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numbers do not allow for the statistically relevant categor-
ization of RR for CKD outcomes based solely on GFR and
albuminuria or proteinuria. Again both the CKiD55 and
European 4C78 trials may be able to address these short-
comings.
1.4: EVALUATION OF CKD
1.4.1: Evaluation of chronicity
1.4.1.1: In people with GFR o60ml/min/1.73m2 (GFR
categories G3a-G5) or markers of kidney
damage, review past history and previous
measurements to determine duration of kidney
disease. (Not Graded)
K If duration is 43 months, CKD is con-
firmed. Follow recommendations for CKD.
K If duration is not 43 months or unclear,
CKD is not confirmed. Patients may have
CKD or acute kidney diseases (including
AKI) or both and tests should be
repeated accordingly.
RATIONALE
When evidence of CKD is first ascertained, proof of
chronicity can be obtained or confirmed by:
(i) review of past measurements of GFR;
(ii) review of past measurements of albuminuria or
proteinuria and urine examinations;
(iii) imaging findings such as reduced kidney size and
reduction in cortical thickness;
(iv) pathological findings such as fibrosis and atrophy;
(v) medical history especially duration of disorders known
to cause CKD;
(vi) repeat measurements within and beyond the 3 month
point.
Chronicity should not be assumed as AKI can present with
similar abnormalities.
Pediatric Considerations
See Pediatric Considerations for next section.
1.4.2: Evaluation of cause
1.4.2.1: Evaluate the clinical context, including personal
and family history, social and environmental
factors, medications, physical examination,
laboratory measures, imaging, and pathologic
diagnosis to determine the causes of kidney
disease. (Not Graded)
RATIONALE
Once the presence of CKD is proven it is essential to establish
a cause for this which will inform specific management and
modify risk projections. The diagnosis will be reached by
standard clinical method (i.e., history examination) and
special investigation, based on knowledge of the common
causes of CKD and their manifestations. Not all evaluations
are required in all patients, and will be directed by clinical
context, and resource availability. For most patients the
following evaluations are indicated:
K Reagent strip urinalysis to detect hematuria or pyuria. If
positive, use urine microscopy to detect RBC casts or
WBC casts.
K Ultrasound to assess kidney structure (i.e., kidney shape,
size, symmetry and evidence of obstruction) as clinically
indicated.
K Serum and urine electrolytes to assess renal tubular
disorders, as clinically indicated.
Many individuals found to have CKD will not have a
primary kidney disease but kidney damage caused by diabetes
mellitus, vascular disease, and hypertension. The issue for the
clinician will be to decide whether the presence of these is a
sufficient explanation and if not, to investigate further. The
prevalence of other conditions will vary depending on region,
age, and other factors.
It is beyond the scope of this guideline to describe how
specific diagnoses are reached but non-nephrologists in the
first instance should review the family history, medications,
symptoms and signs for manifestations of systemic diseases.
Urinalysis should be performed, along with imaging of the
kidneys if obstruction of the urinary tract or polycystic
kidney disease is considered.
Pediatric Considerations
For Recommendations 1.4.1.1 and 1.4.2.1, the statements
would need to be altered for application in pediatric practice
in the following way.
In any child with GFRo60ml/min/1.73m2 (or more
than 1 SD below expected for their age and sex) or with
markers of kidney damage, a complete review of their past
history and previous measurement or estimate of renal
function and full consideration of the clinical context,
including prenatal history, drug exposures of fetus or mother,
genetic conditions, coincident organ abnormalities, physical
examination, fetal and post-natal laboratory measures
including amniotic fluid, pre- and post-natal imaging
and pathologic diagnosis including those of the fetus and
placenta should be used to determine the cause(s) of kidney
disease.
As noted in Pediatric Considerations for Recommendation
1.1.1, developmental renal abnormalities account for as many
as 30-50% of the children with CKD.42 A careful review of all
fetal or maternal exposures, genetic risks factors, and any
relevant information on the intrauterine environment during
gestation are all relevant to the determination of the presence
of CKD either prior to or present immediately at the time of
delivery. An infant may be born with CKD, leading to
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immediate classification within the CGA framework – up to
and including that of dialysis dependency.
1.4.3 Evaluation of GFR
This section describes the various methods by which GFR
can be estimated. We describe laboratory techniques that satisfy
the requirements for robust result reporting and we compare
the accuracy of available equations for the purpose of reporting
eGFR using a single equation where applicable. We emphasize
equations based on standardized measurements of SCr, but also
consider newly developed equations based on standardized
measurements of serum cystatin C (SCysC) because they are
being introduced into clinical practice. We encourage practi-
tioners to have a clear understanding of the value and
limitations of both filtration markers, the importance of
standardization of assays for both, and to understand that
when an accurate assessment of kidney function is required,
direct measurement should be undertaken.
1.4.3.1: We recommend using serum creatinine and
a GFR estimating equation for initial assessment.
(1A)
1.4.3.2: We suggest using additional tests (such as cystatin
C or a clearance measurement) for confirmatory
testing in specific circumstances when eGFR based
on serum creatinine is less accurate. (2B)
RATIONALE
These statements specifically address the need to ensure that
estimating equations are put into routine clinical practice,
and that clinicians understand the utility of further evalua-
tion with additional methods if required.
GFR is measured by the clearance of an exogenous or
endogenous filtration marker.27 All clearance methods are
complex so in clinical practice, GFR is estimated from the
serum concentration of the endogenous filtration marker
creatinine. Cystatin C is an alternative endogenous filtration
marker; other filtration markers are also under evaluation.
The principles of GFR estimation are discussed in the
rationale for recommendations regarding the use of creati-
nine as a filtration marker but the concepts apply to GFR
estimation from all endogenous filtration markers. Specific
comments about GFR estimation using cystatin C are
presented separately.
For most clinical circumstances, estimating GFR from SCr
is appropriate for diagnosis, staging, and tracking the
progression of CKD. However, like all diagnostic tests,
interpretation is influenced by varying test characteristics in
selected clinical circumstances and the prior probability of
disease. In particular, an isolated decreased eGFR in
otherwise healthy individuals is more likely to be false
positive than in individuals with risk factors for kidney
disease or markers of kidney damage. Confirmation of
decreased eGFR by measurement of an alternative endogen-
ous filtration marker (cystatin C) or a clearance measurement
is warranted in specific circumstances when GFR estimates
based on SCr are thought to be inaccurate and when
decisions depend on more accurate knowledge of GFR, such
as confirming a diagnosis of CKD, determining eligibility for
kidney donation, or adjusting dosage of toxic drugs that are
excreted by the kidneys.79 The choice of confirmatory test
depends on the clinical circumstance and the availability of
methods where the patient is treated.
Pediatric Considerations
For Recommendation 1.4.3.1, the statements would need
to be altered for application in pediatric practice in the
following way. The use of SCr and a recently derived pediatric
specific GFR estimating equation, which incorporates a
height term,80 is preferred over the use of SCr alone in the
initial assessment of pediatric renal function.
For Recommendation 1.4.3.2, this guideline is fully
applicable in pediatrics.
1.4.3.3: We recommend that clinicians (1B):
K use a GFR estimating equation to derive
GFR from serum creatinine (eGFRcreat)
rather than relying on the serum creatinine
concentration alone.
K understand clinical settings in which
eGFRcreat is less accurate.
RATIONALE
Estimating GFR from the SCr concentration alone requires
implicit judgments that are difficult in routine clinical care,
including reciprocal transformation, consideration of the
non-GFR determinants, and conversion to the GFR scale.
Using GFR estimating equations provides a more direct
assessment of GFR than SCr alone. The SCr concentration is
influenced by GFR and other physiological processes,
collectively termed ‘‘non-GFR determinants,’’ including
creatinine generation by muscle and dietary intake, tubular
creatinine secretion by organic anion transporters, and
extrarenal creatinine elimination by the gastrointestinal tract
(Figure 10).
GFR estimating equations are developed using regression to
relate the measured GFR to steady state SCr concentration and
a combination of demographic and clinical variables as
surrogates of the non-GFR determinants of SCr. By definition,
GFR estimates using SCr concentration are more accurate in
estimating measured GFR than the SCr concentration alone in
the study population in which they were developed. Sources of
error in GFR estimation from SCr concentration include non-
steady state conditions, non-GFR determinants of SCr,
measurement error at higher GFR, and interferences with
the creatinine assays (Table 11). GFR estimates are less precise
at higher GFR levels than at lower levels.
The clinician should remain aware of caveats for any
estimating equation which may influence the accuracy in a
given individual patient.
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Because of the physiologic and statistical considerations in
developing GFR estimating equations, GFR estimates are less
precise at higher GFR levels than at lower levels. In principle,
equations based on multiple endogenous filtration markers
can overcome some of the imprecision of GFR estimates at
higher levels, due to cancellation of errors from non-
correlated non-GFR determinants.
Pediatric Considerations
This guideline is fully applicable in pediatrics.
1.4.3.4: We recommend that clinical laboratories should (1B):
K measure serum creatinine using a specific
assay with calibration traceable to the inter-
national standard reference materials and
minimal bias compared to isotope-dilution
mass spectrometry (IDMS) reference metho-
dology.
K report eGFRcreat in addition to the serum
creatinine concentration in adults and
specify the equation used whenever reporting
eGFRcreat.
K report eGFRcreat in adults using the 2009
CKD-EPI creatinine equation. An alternative
creatinine-based GFR estimating equation is
acceptable if it has been shown to improve
accuracy of GFR estimates compared to the
2009 CKD-EPI creatinine equation.
When reporting serum creatinine:
K We recommend that serum creatinine con-
centration be reported and rounded to the
nearest whole number when expressed as
standard international units (lmol/l) and
rounded to the nearest 100th of a whole
number when expressed as conventional units
(mg/dl).
Figure 10 |Determinants of the serum level of endogenous
filtration markers. The plasma level (P) of an endogenous
filtration marker is determined by its generation (G) from cells and
diet, extrarenal elimination (E) by gut and liver, and urinary
excretion (UV) by the kidney. Urinary excretion is the sum of
filtered load (GFR X P), tubular secretion (TS), and reabsorption
(TR). In the steady state, urinary excretion equals generation and
extrarenal elimination. By substitution and rearrangement, GFR
can be expressed as the ratio of the non-GFR determinants (G, TS,
TR, and E) to the plasma level. GFR, glomerular filtration rate.
Reprinted with permission of American Society of Nephrology,
Measured GFR as a confirmatory test for estimated GFR, Stevens
LA, Levey AS.79 J Am Soc Nephrol 20: 2305-2313, 2009; permission
conveyed through Copyright Clearance Center, Inc.; accessed
http://jasn.asnjournals.org/content/20/11/2305.full.pdf
Table 11 | Sources of error in GFR estimating using creatinine
Source of error Example
Non-steady state K AKI
Non-GFR determinants of SCr that differ from study populations
in which equations were developed
Factors affecting creatinine generation K Race/ethnicity other than US and European black and white
K Extremes of muscle mass
K Extremes of body size
K Diet and nutritional status
K high protein diet
K creatine supplements
K Muscle wasting diseases
K Ingestion of cooked meat
Factors affecting tubular secretion of creatinine K Decrease by drug-induced inhibition
K trimethoprim
K cimetidine
K fenofibrate
Factors affecting extra-renal elimination of creatinine K Dialysis
K Decrease by inhibition of gut creatininase by antibiotics
K Increased by large volume losses of extracellular fluid
Higher GFR Higher biological variability in non-GFR determinants relative to GFR
K Higher measurement error in SCr and GFR
Interference with creatinine assay K Spectral interferences (e.g., bilirubin, some drugs)
K Chemical interferences (e.g., glucose, ketones, bilirubin, some drugs)
Abbreviations: AKI, acute kidney injury; GFR, glomerular filtration rate; SCr, serum creatinine.
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When reporting eGFRcreat:
K We recommend that eGFRcreat should be
reported and rounded to the nearest whole
number and relative to a body surface area of
1.73m2 in adults using the units ml/min/
1.73m2.
K We recommend eGFRcreat levels less than
60ml/min/1.73m2 should be reported as
‘‘decreased.’’
RATIONALE
The statement is worded this way to acknowledge that
calibration of assays is essential to interpretation of kidney
function measures. This recommendation is directed to
laboratories with the intent to clarify the details of such
calibration and the use of specific equations so as to facilitate
international standardization.81
There are numerous assay methods for creatinine for use
in clinical laboratories. Variation in assigned values for SCr
concentration among methods is greater at low concentra-
tions, corresponding to high levels of GFR. Variation in
assays at low SCr concentrations contributes to imprecision
of GFR estimates at high GFR levels.
Currently available assays fall into two broad categories, the
alkaline picrate (Jaffe) assay and enzymatic assays. In general,
enzymatic assays are less biased compared to a standardized
reference material and less susceptible to interferences. All assays
are available on a number of platforms.
We recommend that laboratories use assays that are
traceable to pure creatinine standards via a valid calibration
hierarchy and that are specific and minimally-biased
compared with isotope-dilution mass spectrometry (IDMS)
reference method results. Results should be traceable to
reference materials and methods listed on the Joint
Committee for Traceability in Laboratory Medicine (JCTLM)
database. Ideally laboratories should move to enzymatic
assays for creatinine measurement: as a minimum, the use of
traditional kinetic or end point Jaffe assays should cease and
be replaced with IDMS aligned Jaffe methods.
Clinical laboratory information systems generally have
access to patient age and sex and thus can report eGFR based
on SCr age and sex, thus providing the clinician with the test
result in units which are recommended for interpretation.
Estimated GFR is now reported together with SCr when
creatinine is ordered in more than 75% of clinical
laboratories in the US.82 In the UK, 93% of NHS laboratories
report eGFR with SCr,83 as is the case in Australia, Canada,
and many European countries.
Selection of a single equation for use, where applicable,
would facilitate communication among providers, patients,
researchers and public health officials. Criteria for selection
should be based on accuracy compared to measured GFR and
usefulness in clinical care and public health.
The interpretation of measured and eGFR is based on
comparison to normative values, which are adjusted for BSA
because of the physiologic matching of GFR to kidney size,
which is in turn related to BSA. The value of 1.73m2 reflects
the average value of BSA of 25-year old men and women in
the USA in 1927.84 While it is known that modern
populations may have different normal values for BSA, the
1.73m2 value will be maintained for normalization purposes.
Drug dosing should be based on GFR which is not
adjusted for BSA. The effect of drug dosing based on GFR
adjusted for BSA compared to GFR unadjusted for BSA has
not been studied rigorously and more precise recommenda-
tions are not available.
Flagging decreased values for eGFR can alert clinicians to
the possibility of AKD or CKD, and may indicate the need for
additional investigations or treatments, including adjustment
of doses of drugs that are excreted by the kidney. However,
values for GFR between 60 and 89ml/min/1.73m2 are mildly
decreased compared to the usual values in young healthy
people. Thus it is important that clinicians appreciate that
eGFR values that are not flagged because they are 460ml/
min/1.73m2 are not necessarily normal.
Evidence Base
Numerous equations have been developed to estimate GFR
or CrCl in adults. In general, GFR estimating equations using
creatinine include age, sex, race, and body size as surrogates
for creatinine generation by muscle. For our review of GFR
estimating equations, we only considered equations that were
developing using assays that were traceable to reference
methods and study populations in which SCr concentration
was measured using traceable assays (Supplemental
Table 1).85
Based on published data, only the Modification of Diet in
Renal Disease (MDRD) Study equation, Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation
and modifications of these equations were developed using
creatinine assays traceable to the international reference
material for creatinine (Table 12).86,87 The Cockcroft and
Gault formula and others were developed before standar-
dization of creatinine assays but cannot be re-expressed
for use with standardized creatinine assays (Supplemental
Table 2).
The MDRD Study equation was developed in 1999 and is
currently recommended for eGFR reporting in adults by the
National Kidney Disease Education Program (NKDEP) and
by the Department of Health in the UK. It uses standardized
SCr, age, sex, and race (black versus white and other) to
estimate GFR adjusted for BSA (ml/min/1.73m2).86,94
Because of imprecision at higher GFR, NKDEP recommends
that eGFR Z60ml/min/1.73m2 computed using the MDRD
Study equation not be reported as a numeric value. For a
similar reason, the UK Department of Health recommends
not reporting eGFR 490ml/min/1.73m2 using the MDRD
Study equation as a numeric value.
The CKD-EPI equation was developed in 2009 and uses
the same four variables as the MDRD Study equation.87 The
CKD-EPI equation had less bias than the MDRD Study
equation, especially at GFRZ60ml/min/1.73m2, a small
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improvement in precision, and greater accuracy (Figure 11).
Most but not all studies from North America, Europe and
Australia show that the CKD-EPI equation is more accurate
than the MDRD Study equation, especially at higher GFR
(Table 13),85 which enables reporting of numeric values
across the range of GFR. At this time, large commercial
clinical laboratories in the US have changed from using the
MDRD Study equation to the CKD-EPI equation for eGFR
reporting.
Lesser bias of the CKD-EPI equation compared to the
MDRD Study equation reflects higher eGFR throughout
most of the range for age and creatinine, especially in
younger individuals, women and whites. Higher eGFR results
in lower prevalence estimates for CKD in these groups
(Figure 12), with more accurate risk relationships of lower
eGFR and adverse outcomes (Figure 13).107
To account for possible differences in muscle mass
and diet according to race, ethnicity and geographic region,
the MDRD Study and CKD-EPI equations have been
modified for use in other racial and ethnic groups and
in other countries. In some, but not all studies, these
modifications are associated with increased accuracy
(Table 14), and should be used in preference to unmodified
equations. Where tested, the CKD-EPI equation and its
modifications were generally more accurate than the MDRD
Study and its modifications. In the absence of specific
modifications for race, ethnicity, or regional difference, it is
reasonable to use the CKD-EPI equation for GFR estimation.
Reliance upon SCr alone is not an appropriate alternative
since the uncertainty about the effect of non-GFR deter-
minants affects interpretation of SCr as much as it affects
interpretation of eGFR. More widespread testing of GFR
estimating equations is necessary to resolve uncertainties
about the need for racial, ethnic, and geographic modi-
fications.108
Pediatric Considerations
This recommendation would need to be altered for applica-
tion in pediatric practice in the following way.
K Creatinine measurements in all infants and children
should be derived from methods that minimize con-
founders and are calibrated against an international
standard.
K eGFRcreat may only be reported when the height of the
child is known by the laboratory.
K If reporting eGFRcreat laboratories should utilize the
most current and accurate pediatric derived equations
based on the demographic and laboratory markers
available.
In infants or small children the level of creatinine when
measured is often below that of the normal ‘bottom range’ of
the adult assay. As such laboratories measuring creatinine in
infants or small children must ensure their lower calibration
samples include the lowest end of the expected range of
values for the group of interest.
As the majority and the most accurate of the published
pediatric eGFRcreat formulas require height, standard labora-
tory reporting of eGFRcreat is neither practical nor recom-
mended in children. In a pediatric CKD population, and
using the plasma disappearance of iohexol as the gold
standard measure of GFR, Schwartz et al. derived a number
of novel GFR prediction equations.80 Their analysis demon-
strated the importance of the height/SCr variable in the
population as it provided the best correlation with the
iohexol GFR (R2¼ 65%). The simplest of such formula, using
only height and SCr and a constant of either 41.3 or 0.413
depending on whether height was expressed as meters or
centimeters respectively, provided 79% of estimated GFRs
within 30% of the iohexol values and 37% of estimated GFRs
within 10% of the iohexol values.
Figure 11 |Performance of the CKD-EPI and MDRD Study equations in estimating measured GFR in the external validation data set.
Both panels show the difference between measured and estimated versus estimated GFR. A smoothed regression line is shown with
the 95% CI (computed by using the lowest smoothing function in R), using quantile regression, excluding the lowest and highest
2.5% of estimated GFR. To convert GFR from ml/min per 1.73m2 to ml/s perm2, multiply by 0.0167. CKI-EPD, Chronic Kidney Disease
Epidemiology Collaboration; CI, confidence interval; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease. Reprinted
with permission from Levey AS, Stevens LA, Schmid CH, et al.87 A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;
150(9): 604-612.
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chapte r 1
Any eGFRcreat formula used in children will preferably be
validated at the appropriate age and level of renal function,
and the laboratory methods used locally will be calibrated or
comparable to those used in the process of developing the
formula being applied. Currently the most robust pediatric
eGFR formulas, derived using iohexol disappearance and
creatinine measurements which were measured centrally and
calibrated and traceable to international standards come
from the CKiDs study.80
The two most common creatinine-based formulas
recommended for use in clinical practice include:
Updated ‘‘Bedside’’ Schwartz equation:
eGFR (ml/min/1.73m2)¼ 41.3 (height/SCr), where height
is in meters and SCr is in mg/dl.
‘‘1B’’ Equation (include blood urea nitrogen [BUN] not
cystatin C):
eGFR (ml/min/1.73m2)¼ 40.7 (height/SCr)0.64 (30/
BUN)0.202, where height is in meters, SCr and BUN are in
mg/dl.
The additional recommendation for laboratory reporting
of SCr is fully applicable in pediatrics.
When the individual clinician has information regarding
current and accurate height and applies the appropriate
pediatric formula, the recommendation to report an
individual child’s eGFRcreat value of less than 60ml/min/
1.73m2 as ‘‘decreased,’’ would be applicable in children over
the age of 2 years.
1.4.3.5: We suggest measuring cystatin C in adults with
eGFRcreat 45-59 ml/min/1.73m
2 who do not have
markers of kidney damage if confirmation of CKD
is required. (2C)
K If eGFRcys/eGFRcreat-cys is also o60ml/min/
1.73m2, the diagnosis of CKD is confirmed.
K If eGFRcys/eGFRcreat-cys is Z60ml/min/1.73m
2,
the diagnosis of CKD is not confirmed.
RATIONALE
A major foundation of this guideline is that CKD classifica-
tion and staging should be influenced primarily by clinical
prognosis. As will be reviewed in the sections below,
abundant evidence has shown that GFR estimates based on
cystatin C are more powerful predictors of clinical outcomes
than creatinine-based eGFR. These findings have been
strongest for mortality and CVD events, and the prognostic
advantage of cystatin C is most apparent among individuals
with GFR 445ml/min/1.73m2. In addition, new findings
show that using cystatin C in addition to SCr can lead to
improved accuracy of GFR estimation, including CKD
classification. In the opinion of the Work Group, these
considerations warrant new recommendations for GFR
estimation using cystatin C.
Evidence Base
Evidence supports the use of cystatin C-based eGFR within
the population of persons diagnosed with CKD based on an
eGFRcreat 45-59 ml/min/1.73 m
2 (G3a) but without albumin-
uria (A1) or other manifestations of kidney damage. This
group represents 3.6% of the US population and 41% of
people in the US estimated to have CKD based on eGFRcreat
and urine ACR alone (Figure 8), and there has been
substantial controversy over whether or not these persons
have CKD. Data described below indicate that use of cystatin
C to estimate GFR in this population leads to more accurate
estimation of GFR and prediction of risk for future adverse
events.
In several studies, eGFRcys has been measured in
populations with and without eGFRcreat o60ml/min/
1.73m2, and participants were separated into those with
and without eGFRcyso60ml/min/1.73m2 (Figure 14). Those
with both eGFRcreat and eGFRcyso60ml/min/1.73m2, about
two-thirds of those with eGFRcreat o60ml/min/1.73m2, had
Figure 12 |Comparison of distribution of GFR and CKD
prevalence by age (NHANES 1999-2004). GFR was categorized
on the basis of the classification system established by the
NKF-KDOQI. Top. Distribution of estimated GFR, by 4-ml/min per
1.73m2 categories. Values are plotted at the midpoint. Bottom.
Prevalence of CKD, by age. CKD, chronic kidney disease;
GFR, glomerular filtration rate; NKF-KDOQI, National Kidney
Foundation-Kidney Disease Outcomes Quality Initiative; NHANES,
National Health and Nutrition Examination Survey. Reprinted with
permission from Levey AS, Stevens LA, Schmid CH, et al.87 A new
equation to estimate glomerular filtration rate. Ann Intern Med
2009; 150(9): 604-612.
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markedly elevated risks for death, CVD, and ESRD end points
compared with persons with eGFRcreat 460ml/min/1.73m
2.
The Work Group therefore considers this group
to have ‘‘confirmed CKD.’’ In contrast, about one-third of
those with eGFRcreato60ml/min/1.73m2 had eGFRcys460ml/
min/1.73m2 and this group were similar in risk for adverse
outcomes as persons with eGFRcreat460ml/min/1.73m
2.
New data from CKD-EPI also showed improved accuracy
in GFR estimation using both creatinine and cystatin C
(eGFRcreat-cys) compared to either marker alone. In the
subgroup with eGFRcreat 45-59ml/min/1.73m
2, the com-
bined equation correctly reclassified 16.8% of those with
eGFR 45-59ml/min/1.73m2 to measured GFR Z60ml/min/
1.73m2.113
The consensus of the Work Group was therefore that the
large group of persons with eGFRcreat 45-59ml/min/1.73m
2
without markers of kidney damage, but with eGFRcys/
eGFRcreat-cys Z60ml/min/1.73m
2 could be considered not to
have CKD. The removal of the diagnosis and label of CKD may
be reassuring to patients and may help clinicians to focus their
efforts on higher risk CKD patients.
The guideline statement suggesting the use of eGFRcys/
eGFRcreat-cys requires several important qualifiers. First,
clinicians may not want or need to confirm the diagnosis
of CKD in patients with eGFRcreat 45-59ml/min/1.73m
2
without markers of kidney damage, either because the
likelihood of CKD is high because of the presence of risk
factors for CKD or presence of complications of CKD. Second,
cystatin C is not universally available, so it may not be practical
for a clinician to request a cystatin C blood test. Third, in
certain clinical settings, the cost of measuring cystatin C (US
$1–5) may be prohibitive. For all these reasons, the guideline
statement 1.4.3.5 is stated as a suggestion.
In addition to the population described above, eGFRcys
may be useful as a confirmatory test in situations where
either the eGFRcreat may be inaccurate or biased, or when the
clinical scenario warrants a secondary test (Recommendation
1.4.3.2). In these clinical situations, a clearance measurement
using an exogenous filtration marker may be optimal when it
is available. The measurement of eGFRcys/eGFRcreat-cys would
be a relatively low-cost, feasible alternative when GFR
measurement is not practical. The Work Group believed that
measured urinary CrCl was an inferior confirmatory test
relative to either GFR measurement or GFR estimation using
both creatinine and cystatin C.
If cystatin C testing is desired, it is very important that
clinicians understand principles of GFR estimation using cystatin
C. As with creatinine, GFR should be estimated from cystatin C
and an appropriate equation should be chosen for the specific
clinical population (Recommendation 1.4.3.6), and an assay be
chosen for measurement that is traceable to the international
standard reference material (Recommendation 1.4.3.7).
Pediatric Considerations
The utility of this specific statement to pediatrics is unclear as
the vast majority of children with significant reductions in
GFR, e.g., below 60ml/min/1.73m2, have either structural
abnormalities or findings of renal damage as evidenced by
urinary or serum abnormalities. It is very unlikely that
isolated reduction in GFR would occur as in older adults. As
such, the confirmation of CKD will be made on criteria
beyond that of GFR alone.
1.4.3.6: If cystatin C is measured, we suggest that health
professionals (2C):
K use a GFR estimating equation to derive GFR
from serum cystatin C rather than relying on the
serum cystatin C concentration alone.
K understand clinical settings in which eGFRcys
and eGFRcreat-cys are less accurate.
Overall
Sex
Female
Male
Diabetes
No
Yes
Hypertension
No
Yes
Age, y
<65
≥65
Race/ethnicity
White
Black
Asian
Favors
MDRD
Favors
CKD-EPI
No. of 
Cohorts
23
23
23
23
23
22
23
15
5
10
20
21
–0.1 0 0.1 0.2
NRI (95% CI)
All-cause mortality
Favors
MDRD
Favors
CKD-EPI
No. of 
Cohorts
18
18
17
18
18
17
18
13
4
5
15
18
–0.1 0 0.1 0.2
NRI (95% CI)
Cardiovascular mortality
Favors
MDRD
Favors
CKD-EPI
No. of 
Cohorts
5
5
3
2
3
5
5
3
2
2
5
5
–0.1 0 0.1 0.2
NRI (95% CI)
End-stage renal disease
Figure 13 |Meta-analysis of NRI for all-cause mortality, CVD mortality, and ESRD. NRI summarizes the risk of clinical outcomes among
participants who are reclassified from one estimated GFR category using the MDRD Study equation to another estimated GFR category
using the CKD-EPI equation compared with those who are not reclassified. NRI greater than zero favors the CKD-EPI equation. NRI less than
zero favors the MDRD Study equation. The sizes of the data markers are proportional to the inverse of the variance of the NRIs. CKD-EPI,
Chronic Kidney Disease Epidemiology Collaboration; CVD, cardiovascular disease; ESRD, end-stage renal disease; GFR, glomerular filtration
rate; MDRD, Modification of Diet in Renal Disease; NRI, net reclassification improvements. Reprinted with permission from Matsushita K,
Mahmoodi BK, Woodward M, et al.107 Comparison of risk prediction using the CKD-EPI equation and the MDRD Study equation for
estimated glomerular filtration rate. JAMA 2012; 307(18): 1941-1951. Copyright & (2012) American Medical Association. All rights reserved.
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RATIONALE
Cystatin C is licensed for use in some countries in
Europe and has been approved by the FDA as a measure
of kidney function in the United States for nearly
10 years. In certain regions, notably Sweden and parts
of China, eGFR is routinely estimated by both creatinine
and cystatin C. As with creatinine, GFR estimates using
cystatin C are more accurate in estimating measured
GFR than the SCysC concentration alone. As with crea-
tinine, sources of error in GFR estimation from SCysC
concentration include non-steady state conditions, non-
GFR determinants of SCysC, measurement error at
higher GFR, and interferences with the cystatin C assays
(Table 15).
Pediatric Considerations
For Recommendation 1.4.3.6, this guideline is fully applicable
in pediatrics. See Recommendation 1.4.3.7 for details.
In terms of clinical settings where eGFRcys might be less
accurate, it should be noted that Schwartz et al. determined
that the only variable that explained the outlier values of
estimated GFR (in both univariate and multivariate for-
mulas) was heavier weight; race, high blood pressure,
albumin levels and use of steroids did not contribute.115
Figure 14 |Association of CKD definitions with all-cause mortality and ESRD. CKD, chronic kidney disease; ESRD, end-stage renal
disease. Reprinted with permission from Peralta CA, Shlipak MG, Judd S, et al.114 Detection of chronic kidney disease with creatinine, cystatin
C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011; 305(15):
1545-1552. Copyright & (2011) American Medical Association. All rights reserved.
Table 15 | Sources of error in GFR estimating using cystatin C
Source of error Example
Non-steady state K AKI
Non-GFR determinants of SCysC that differ from study populations in which
equations were developed
Factors affecting cystatin C generation K Race/ethnicity other than US and European black and white
K Disorders of thyroid function
K Administration of corticosteroids
K Other hypothesized factors based on epidemiologic associations
(diabetes, adiposity)
Factors affecting tubular reabosrption of cystatin C None identified
Factors affecting extra-renal elimination of cystatin C Increased by severe decrease in GFR
Higher GFR K Higher biological variability in non-GFR determinants relative to
GFR
K Higher measurement error in SCysC and GFR
Interference with cystatin C assay K Heterophilic antibodies
Abbreviations: AKI, acute kidney injury; GFR, glomerular filtration rate, SCysC, serum cystatin C.
50 Kidney International Supplements (2013) 3, 19–62
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1.4.3.7: We recommend that clinical laboratories that
measure cystatin C should (1B):
K measure serum cystatin C using an assay
with calibration traceable to the interna-
tional standard reference material.
K report eGFR from serum cystatin C in
addition to the serum cystatin C concentra-
tion in adults and specify the equation
used whenever reporting eGFRcys and
eGFRcreat-cys.
K report eGFRcys and eGFRcreat-cys in adults
using the 2012 CKD-EPI cystatin C and
2012 CKD-EPI creatinine-cystatin C equa-
tions, respectively, or an alternative cystatin
C-based GFR estimating equations if they
have been shown to improve accuracy of
GFR estimates compared to the 2012 CKD-
EPI cystatin C and 2012 CKD-EPI creati-
nine-cystatin C equations.
When reporting serum cystatin C:
K We recommend reporting serum cysta-
tin C concentration rounded to the
nearest 100th of a whole number when
expressed as conventional units (mg/l).
When reporting eGFRcys and eGFRcreat-cys:
K We recommend that eGFRcys and
eGFRcreat-cys be reported and rounded to
the nearest whole number and relative to a
body surface area of 1.73m2 in adults using
the units ml/min/1.73m2.
K We recommend eGFRcys and
eGFRcreat-cys levels less than 60 ml/min/
1.73m2 should be reported as ‘‘decreased.’’
RATIONALE
As for SCr, reporting eGFR using cystatin C in addition to
cystatin C will facilitate clinician’s use of cystatin C for GFR
estimation. It is important to acknowledge that calibration of
assays is essential to interpretation of kidney function
measures. Cystatin C is measured by a variety of immu-
noassays and, as for creatinine, there can be variation among
methods in reported SCysC concentration but reported
analytic variation appears less common than with creatinine.
In June 2010 the Institute for Reference Materials and
Measurements (IRMM) released a reference material (ERM-
DA471/IFCC) for cystatin C measurement. Reagent manu-
facturers are in the process of recalibrating their assays
against this standard which will enable standardized report-
ing of cystatin C and eGFR results. This recommendation is
directed to laboratories with the intent to clarify the details of
such calibration and the use of specific equations so as to
facilitate international standardization.
Evidence Base
Numerous equations have been developed to estimate GFR.
Some equations include cystatin C as the only variable, while
others include, age, sex, or race, but the magnitude of
coefficients for these variables are smaller than in creatinine-
based equations, presumably reflecting less contribution of
muscle to cystatin C generation than to creatinine generation.
Equations without race are a potential advantage for cystatin
C-based estimating equations in non-black, non-white
populations.
For our review of GFR estimating equations, we only
considered equations that were developed using assays that
were traceable to the new reference methods and study
populations in which SCysC concentration was measured
using traceable assays. At this time, only the equations
developed by CKD-EPI are expressed for use with standar-
dized SCysC (Table 16), including equations developed in
CKD populations in 2008116,117 and re-expressed for use with
standardized cystatin C in 2011, and equations developed in
diverse populations in 2012.113 Equations using assays that
are not traceable to the the reference standard are listed in
Supplemental Table 3.
The 2012 creatinine-cystatin C equation is more
accurate than equations using creatinine or cystatin C
separately (Figure 15), and more accurate than the
2008 creatinine-cystatin C equation (Table 17). The average
of the GFR computed by the equations using creatinine
and cystatin C separately is similar to the GFR computing
using the creatinine-cystatin C equations. The 2012
cystatin C equation has similar accuracy to the 2009
creatinine equation described above but does not require
use of race, and may be more accurate in non-black,
non-white populations or in clinical conditions with
variation in non-GFR determinants of SCr. We antici-
pate the development of additional equations using cystatin
C in the future and recommend that they be compared with
the CKD-EPI 2012 cystatin C and creatinine-cystatin C
equations as well as with the CKD-EPI 2009 creatinine
equation.
Pediatric Considerations
For Recommendation 1.4.3.7 this set of statements would
need to be altered for application in pediatric practice in the
following way:
K Measure SCysC using an immunonephelometrically
determined method in which the assay is calibrated and
traceable to the international standard reference material.
K Report eGFRcys in addition to the SCysC concentration in
children.
K Report eGFRcys in children specifying the specific
equation used.
Based on their recent work comparing particle-enhanced
nephelometric to turbidometric immunoassays for cystatin C
in a pediatric population with significant reduction in GFR
(median GFR B45ml/min/1.73m2), Schwartz et al. demon-
strated less bias for the nepholometric value and that its
reciprocal showed a substantially improved correlation to the
iohexol GFR (0.87 versus 0.74) when compared to that of the
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turbidometric assay.115 This demonstrates the importance of
using an assay calibrated and traceable to the international
standard reference material.
Numerous pediatric specific and derived eGFRcys formulas
have been published, the most current and recent by
Schwartz115 who derives the newest available from a
validation set from the CKiD study and compares those
results to 3 other well-recognized formulas from the
literature, namely Zapitelli et al.,118 Filler and Lepage,119
and Hoek et al.120
Their results demonstrate that the newest univariate
cystatin C formula derived from the CKiD cohort has
excellent accuracy with 82.6% of eGFRcys within 30% of the
true measured iohexol GFR and 37.6% within 10% of the
true measured iohexol GFR. Likewise the bias of 0.3% and
correlation of 0.85 are the best of all formulas reported to
date. The formula they use to obtain these values is: 70.69 
(cystatin c)-0.931.
Of note, their final multivariate equation, when applied to
the validation set and using height/SCr, nepholemetric
cystatin C, BUN, sex, and an adjusted height term
demonstrated the best accuracy reported in pediatric studies
to date, 91% and 45% within 30% and 10% of the true GFR,
respectively; with a bias of only 0.2 and correlation of 0.92.
1.4.3.8: We suggest measuring GFR using an exogenous
filtration marker under circumstances where more
accurate ascertainment of GFR will impact on
treatment decisions. (2B)
RATIONALE
In clinical practice, there may be a requirement to measure
GFR when the need for a ‘truer’ more precise value is
identified (such as for organ donation or for dosing of toxic
drugs). The intention of this statement is to recognize that
specialty centers for kidney disease, usually tertiary referral
centers, should have the capacity to measure GFR using
exogenous filtration markers as a recognized specialist
service. We recognize that this ability does not currently
constitute the definition of specialty kidney referral centers
and that it may be problematic, but resources to ensure
accurate measurement ought to be made available. Given that
these specific measurements require levels of rigor and
reproducibility similar to those of laboratory calibration
issues, specialist centers would be the right place to suggest
that these facilities be made available.
Evidence Base
GFR is measured as the clearance of an exogenous filtration
marker. The ‘‘gold standard’’ method is the urinary clearance
of inulin during a continuous intravenous infusion. To
simplify the procedure there are a number of alternative
clearance methods and alternative filtration markers, with
minor differences among them.79 For all measurement
methods, measured GFR should be reported as described
for eGFR.
Table 18 summarizes the strengths and limitations of
clearance methods and filtration markers for clearance
measurements. Thus measured GFR may also be associated
with error, and in evaluation of GFR estimating equations,
random error in GFR measurement is a source of some of the
imprecision in GFR estimating equations.27,121 In principle,
the magnitude of random error in GFR measurements is
likely to be smaller than errors in GFR estimation using
creatinine and cystatin C due to conditions listed in Tables 11
and 15.
International Relevance
The calculation of eGFR using these equations usually
requires computer programming and some processes for
quality monitoring. Nonetheless the statements are here to
serve as ‘best practice’ recommendations so that these can be
Figure 15 |Performance of three equations for estimating
GFR. Panel a shows the median difference between measured
and estimated GFR. The bias is similar with the equation using
creatinine alone, the equation using cystatin C alone, and the
combined creatinine–cystatin C equation. Panel b shows the
accuracy of the three equations with respect to the percentage
of estimates that were greater than 30% of the measured
GFR (1 – P30). Whiskers indicate 95% confidence intervals. GFR,
glomerular filtration rate; P30, percentage of estimated GFR values
within 30% of measured GFR. From N Engl J Med, Inker LA,
Schmid CH, Tighiouart H, et al.113 Estimating glomerular filtration
rate from serum creatinine and cystatin C. 367: 20-29. Copyright
& 2012 Massachusetts Medical Society. Reprinted with permission
from Massachusetts Medical Society.
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aspired to over time in those locations where these
recommendations are currently not able to be implemented.
The Work Group appreciated that not all laboratories have
capabilities to assay cystatin C. Different countries and
regions will have different availabilities for measurement of
GFR. The statement about GFR measurements mostly applies
to countries with tertiary care services such as kidney
transplantation and oncology.
Implications for Clinical Practice and Public Policy
It is important for clinicians to understand various methods
for estimating and measuring kidney function and the
situations in which specific methods may be superior in
clinical decision making about treatment and referral.
Standardized assays and robust equations are important
for epidemiological and planning purposes so that public
policy can be informed by more accurate estimates of CKD,
which may be possible with improved standardization of
both assays and equations.
In different parts of the world, different assays are used
and equations for estimating eGFR may differ. Thus,
appreciating and understanding local standards is important
for individual patients who may travel, and for comparative
research across countries or regions.
In the event that a clinician requires measurement of GFR
instead of an estimate, knowledge of these different tests and
availability of them is important. Situations in which
measurement would be required are likely quite infrequent
Table 18 | Strengths and limitations of GFR measurement methods and markers
Approach Strengths Limitations
Methods
Urinary clearance
Bladder catheter and continuous
intravenous infusion of marker
K Gold standard method K Invasive
Spontaneous bladder emptying K Patient comfort
K Less invasive
K Possibility of incomplete bladder emptying
K Low flow rates in people with low levels of GFR
Bolus administration of marker K Shorter duration K Rapidly declining plasma levels at high levels of GFR
K Longer equilibration time in extracellular volume expansion
24 h urinary collection K Cumbersome
K Prone to error
Plasma clearance K No urine collection required
K Potential for increased precision
K Overestimation of GFR in extracellular volume expansion
K Inaccurate values with 1-sample technique, particularly at
lower GFR levels
K Longer duration of plasma sampling required for low GFR
Nuclear imaging K No urine collection or repeated
blood samples required
K Relatively short duration
K Less accurate
Markers
Inulin K Gold standard
K No side effects
K Expensive
K Difficult to dissolve and maintain into solution
K Short supply
Creatinine K Endogenous marker, no need
for administration
K Assay available in all clinical
laboratories
K Secretion can vary among and within individuals
Iothalamate K Inexpensive
K Long half life
K Probable tubular secretion
K Requirement for storage, administration, and disposal of
radioactive substances when 125I used as tracer
K Use of non-radioactive iothalamate requires expensive assay
K Cannot be used in patients with allergies to iodine
Iohexol K Not radioactive
K Inexpensive
K Sensitive assay allows for low dose
K Possible tubular reabsorption or protein binding
K Use of low doses requires expensive assay
K Cannot be used in patients with allergies to iodine
K Nephrotoxicity and risk for allergic reactions at high doses
EDTA K Widely available in Europe K Probable tubular reabsorption
K Requirement for storage, administration, and disposal of
radioactive substances when 51Cr is used as tracer
DTPA K Widely available in the US
K New sensitive and easy to
use assay for gadolinium
K Requirement for storage, administration, and disposal of
radioactive substances when 99mTc used as tracer
K Requires standardization for 99mTc
K Dissociation and protein binding of 99mTc
K Concern for NSF when gadolinium is used as the tracer
Abbreviations: DTPA, diethylenetriamine pentaacetic acid; EDTA, ethylenediamine tetraacetic acid; GFR, glomerular filtration rate; NSF, nephrogenic systemic fibrosis.
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but include donor evaluation in kidney transplantation and
use of toxic drugs which have a narrow therapeutic range. We
acknowledge that drug development and clinical observation
programs may not define the various thresholds with
sufficient granularity to require greater accuracy than is
provided by eGFRcreat. Guidance is evolving regarding kidney
function evaluation during drug development programs.13
There are no direct implications for public policy for the
statement about GFR measurement.
Areas of Controversy, Confusion, or Non-consensus
The Work Group recognizes that no single creatinine-based
estimating equation will perform optimally in all clinical
circumstances and that there may be changes in the
performance of estimating equations over time and in
different regions. However, for the purpose of eGFR
reporting, it is important to select a single equation within
a region or country. At the writing of this guideline, in
North America, Europe, and Australia, the advantages of the
CKD-EPI equation at higher GFR make it more applicable
than the MDRD Study equation for general practice and
public health.
While cystatin C offers some advantages over SCr as the
basis of estimating equations, the cost of the assay and
potential lack of standardization across laboratories for this
‘newer’ test limit our ability to recommend it as a preferred
or even usual second test after creatinine. We recognize that
these factors may lead to variations in implementation. The
recommendation to consider confirmatory or additional
testing if there is a need for more accurate determination of
GFR is important. That there are other laboratory markers to
estimate GFR (i.e., cystatin C) is stated here as there has been
accumulating data to support its use in these situations. We
have specifically mentioned cystatin C because of these data.
Clarification of Issues and Key Points
It is important for clinicians to appreciate the need for
standardized assays and standardized equations for labora-
tory reporting of eGFR. Changes in laboratory assays or
calculation methods should be reported to clinicians in order
to avoid confusion when serially following individuals. This
is because values in an individual might indicate a worsening
or improvement in eGFR which may be attributable to
different assays or calculation methods, rather than a
reflection of true change.
When precise information about GFR is required, direct
measurement using reliable methods should be pursued.
Pediatric Considerations
For Recommendation 1.4.3.8 this guideline is fully applicable
in pediatrics.
1.4.4 Evaluation of albuminuria
1.4.4.1: We suggest using the following measurements
for initial testing of proteinuria (in descending
order of preference, in all cases an early
morning urine sample is preferred) (2B):
(1) urine albumin-to-creatinine ratio (ACR);
(2) urine protein-to-creatinine ratio (PCR);
(3) reagent strip urinalysis for total protein
with automated reading;
(4) reagent strip urinalysis for total protein
with manual reading.
1.4.4.2: We recommend that clinical laboratories report
ACR and PCR in untimed urine samples in
addition to albumin concentration or protein-
uria concentrations rather than the concentra-
tions alone. (1B)
1.4.4.2.1: The term microalbuminuria should
no longer be used by laboratories.
(Not Graded)
1.4.4.3: Clinicians need to understand settings that
may affect interpretation of measurements of
albuminuria and order confirmatory tests as
indicated (Not Graded):
K Confirm reagent strip positive albuminuria
and proteinuria by quantitative laboratory
measurement and express as a ratio to
creatinine wherever possible.
K Confirm ACRZ30mg/g (Z3mg/mmol) on
a random untimed urine with a subsequent
early morning urine sample.
K If a more accurate estimate of albuminuria
or total proteinuria is required, measure
albumin excretion rate or total protein
excretion rate in a timed urine sample.
RATIONALE
We recommend measurement of urinary albumin because it
is relatively standardized and because it is the single most
important protein lost in the urine in most chronic kidney
diseases. Use of urinary albumin measurement as the
preferred test for proteinuria detection will improve the
sensitivity, quality, and consistency of approach to the early
detection and management of kidney disease.
By contrast, laboratory tests purporting to measure
urinary total protein are commonly flawed, often being
standardized against, and predominantly sensitive to, albu-
min. They have poor precision at low concentrations and
demonstrate poor between-laboratory agreement while being
insensitive, non-specific, and susceptible to a range of false-
positive and false-negative problems. There may occasionally
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be clinical reasons for a specialist to use PCR instead of
ACR to quantify and monitor significant levels of proteinuria
(e.g., in patients with monoclonal gammopathies).
Commonly used reagent strip devices measuring total
protein are insufficiently sensitive for the reliable detection of
proteinuria, do not adjust for urinary concentration, and are
only semi-quantitative. Furthermore, there is no standardization
between manufacturers. The use of such strips should be
discouraged in favor of quantitative laboratory measurements of
albuminuria or proteinuria. When used, reagent strip results
should be confirmed by laboratory testing (Figure 16).
The combination of reagent strips with automated reader
devices can improve inter-operator variability. More recently
launched reagent strip devices capable of producing albumin
or total protein results as a ratio to urinary creatinine require
further evaluation to provide evidence that they have
equivalent sensitivity and specificity to laboratory tests and
are economically advantageous.
Although the reference point remains the accurately timed
24-hour specimen, it is widely accepted that this is a difficult
procedure to control effectively and that inaccuracies in
urinary collection may contribute to errors in estimation of
protein losses. In practice, untimed urine samples are a
reasonable first test for ascertainment of albuminuria.
An EMU (‘first pass’) sample is preferred since it correlates
well with 24-hour protein excretion, has relatively low
Opportunistic finding
of positive reagent
strip result for albumin
or total protein
Inspect urine
Repeat
reagent strip
positive?
Cloudy?
Measure urinary ACR
Yes
MSU for C&S
Treat infection if positive
Yes
Patient requires testing
for proteinuria as part of
CKD detectionor
surveillance program
No
ACR >300 mg/g
(>30 mg/mmol)?
Severely increased
proteinuria
ACR ≥30 mg/g
(≥3mg/mmol)?
Yes
No
Send 2 further EMU samples for ACR
within the next 2 months
Yes
EMU
ACR ≥30 mg/g
(≥3 mg/mmol) in at
least 1of 2
subsequent
samples? 
Continue routine
observation
Refer for specialist
assessment e.g.,
possible biopsy
Hematuria?
Yes
Yes
No Moderately increased
albuminuria
No
No
No
Figure 16 | Suggested protocol for the further investigation of an individual demonstrating a positive reagent strip test for
albuminuria/proteinuria or quantitative albuminuria/proteinuria test. Reagent strip device results should be confirmed using
laboratory testing of the ACR on at least two further occasions. Patients with two or more positive (Z30mg/g or Z3mg/mmol) tests on
early morning samples 1-2 weeks apart should be diagnosed as having persistent albuminuria. The possibility of postural proteinuria should
be excluded by the examination of an EMU. PCR measurement can be substituted for the ACR but is insensitive in the detection of
moderately increased albuminuria/proteinuria. Approximate PCR equivalent to an ACR of 30mg/mmol is 50mg/mmol. ACR, albumin-to-
creatinine ratio; C&S, culture and sensitivity; CKD, chronic kidney disease; EMU, early morning urine; MSU, mid-stream urine; PCR, protein-to-
creatinine ratio. aConsider other causes of increased ACR (e.g., menstrual contamination, uncontrolled hypertension, symptomatic urinary
tract infection, heart failure, other transitory illnesses, and strenuous exercise), especially in the case of type 1 diabetes present for less than
5 years. The presence of hematuria may indicate non-diabetic renal disease. This figure was published and adapted from Lamb EJ, Price
CP.122 Kidney function tests, in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, eds Burtis CA, Ashwood E, Bruns DE, 5th
edition, pp 669-708, 2012. Copyright Elsevier.
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intra-individual variability, and is required to exclude the diag-
nosis of orthostatic (postural) proteinuria. However, a random
urine sample is acceptable if no EMU sample is available.
The concentration of protein or albumin in a urine sample
will be affected by hydration (i.e., how diluted or concen-
trated a urine sample is). Creatinine excretion is considered
to be fairly constant throughout the day and it has become
customary to correct for urinary concentration by expressing
either the protein or albumin concentrations as a ratio to the
creatinine concentration in the same sample.
Timed urine collections may be used for confirmatory
purposes but are not required except in circumstances in
which untimed urine ACR is less accurate. It is worthwhile
noting that albumin and protein excretion display consider-
able biological variability and may be increased by a variety of
pathological and non-pathological factors. Consequently,
confirmation of increased excretion rates is recommended.
Evidence Base
Why is albumin measurement being recommended instead
of total protein? Urine albumin measurement provides a
more specific and sensitive measure of changes in glomerular
permeability than urinary total protein.123–125 There is
substantial evidence linking increased albuminuria to
outcomes of CKD4,30 (e.g., CKD Prognosis Consortium2–5,
Nord-Trøndelag Health Study [HUNT 2]125a, Prevention of
Renal and Vascular Endstage Disease [PREVEND]125b). There
is also evidence that urinary albumin is a more sensitive test
to enable detection of glomerular pathology associated with
some other systemic diseases including diabetes, hyperten-
sion and systemic sclerosis.126–129
In health, relatively small amounts of albumin (o30mg/
24 hours) are lost in the urine. Because of this, and
additionally because total protein assays are imprecise and
insensitive at low concentrations, relatively large increases in
urine albumin excretion can occur without causing a
significant measurable increase in urinary total protein.125
Total protein measurement is problematic in urine due to:
large sample-to-sample variation in the amount and
composition of proteins; high and variable concentrations
of non-protein interfering substances relative to the protein
concentration; and high inorganic ion content. All these
factors affect the precision and accuracy of the various
methods. Most laboratories currently use either turbidimetry
or colorimetry130 to measure total protein and as with urine
reagent strip analysis, these methods do not give equal
analytical specificity and sensitivity for all proteins which can
contribute to diverse estimates of proteinuria preva-
lence.131,132 Most methods tend to react more strongly with
albumin than with globulin and other non-albumin pro-
teins.34,133–135 There are significant interferences causing
falsely high results.136–138. There is no reference measurement
procedure and no standardized reference material for urinary
total protein listed by the JCTLM. The variety of methods
and calibrants in use means that there is inevitably significant
between-laboratory variation.139–141 Since a variable mixture
of proteins is measured, it is difficult to define a standardized
reference material.
How should albumin be measured and reported?
Albumin should be measured using immunological assays
capable of specifically and precisely quantifying albumin at
low concentrations and of producing quantitative results over
the clinically relevant range. Currently urinary albumin is
predominantly measured by diagnostic laboratories using
turbidimetric assays.130 At present there is no reference
measurement procedure or standardized reference material
for urine albumin listed by the JCTLM, although the NKDEP
and the International Federation of Clinical Chemistry and
Laboratory Medicine have recently established a joint
committee to address these issues.142,143 At present, most
assays are standardized against a serum-based calibrant (CRM
470) distributed by the IRMM of the European Commission,
as has previously been recommended by KDIGO.31
Albumin concentration should be reported as a ratio to
urinary creatinine concentration (mg/mmol or mg/g). ACR
results should be expressed to one decimal place (mg/mmol) or
whole numbers (mg/g). Both enzymatic and Jaffe assays are
suitable for the measurement of creatinine in urine. We suggest
that the term ‘microalbuminuria’ no longer be used because it
can be misleading in suggesting that the albumin may be small or
different in some way. The proposed albuminuria categories
A1-3 are a more clinically meaningful way to express information
about categories within the continuum of albumin excretion.
Reagent strip point-of-care testing devices capable of
measuring low concentrations of albumin are also available
producing both semi-quantitative and fully quantitative ACR
results. Reasonable analytical144–147 and diagnostic perfor-
mance has been demonstrated.148–150 While studies of these
devices have been somewhat limited in size, they demonstrate
their potential to play a significant role in the care pathway of
patients suspected of having CKD.
Why are reagent strip devices for protein measurement
considered less accurate than laboratory measurement?
Reagent strip devices for proteinuria detection have been in use
for more than 50 years. As discussed earlier, a positive reagent
strip result is also associated with outcomes of CKD. Such
devices have been used to support screening programs in some
countries,151–153 although there appears to be no evidence
supporting such screening of unselected populations.154
Although purporting to measure total protein, the reagent
pad is most sensitive to albumin.155–157 There is evidence that
strips from different manufacturers perform differently at the
cutoff (‘þ ’) concentration of 300mg/l and degrees of ‘plus-
ness’ between different manufacturers don’t always corres-
pond to the same nominal concentration of protein in
urine.124 Concentrated urines may give a color change in the
positive range of a reagent strip device even though protein
loss remains normal and vice versa. False-positive results may
occur if the urine is alkalinized (e.g., due to urinary tract
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infection) or in the presence of quaternary ammonium
compounds that alter the pH of the urine. The performance
of reagent strips is operator-dependent158 and affected by the
presence of colored compounds such as bilirubin and certain
drugs (e.g., ciprofloxacin, quinine, and chloroquine).159
Reagent strips cannot reliably distinguish between protein-
uria categories124,157 and show relatively poor diagnostic
accuracy for proteinuria detection.160,161 In the Australian
Diabetes, Obesity and Lifestyle (AusDiab) study, a reagent
strip reading of þ or greater had 58% and 99% sensitivity
for detecting ACRZ30mg/g (Z 3mg/mmol) andZ300mg/
g (Z30mg/mmol), respectively. 47% of individuals who
tested þ or greater had an ACR Z30mg/g (Z 3mg/mmol)
on laboratory testing.162
Automated devices capable of reading the color changes of
reagent strips using reflectance spectrometry are available.
These reduce inter-operator variability and improve diag-
nostic accuracy.150,158,163 A creatinine test pad has been added
to some reagent strip systems to enable a PCR to be reported
and so reduce the intra-individual variation seen with
random urine collections. Such devices have been shown to
be suitable for ruling out significant proteinuria (4300mg/
24 hours) in an outpatient setting.149
Correcting for urinary dilution. Since creatinine excretion
in the urine is fairly constant throughout the 24-hour period,
measurement of ACR (or PCR) allows correction for
variations in urinary concentration.164,165 ACR is a suitable
alternative to timed measurement of urine albumin
loss.143,166–170 PCR on random or early morning untimed
samples shows good diagnostic performance and correlation
with 24-hour collection.160,163,171–177
Expressing albumin as a ratio to creatinine reduces intra-
individual variability: lowest variability for the ACR has been
reported in EMU samples as opposed to other untimed
samples or timed collections.142,178 In one study albumin
variability was reduced from 80% to 52% when expressed as
an ACR rather than an albumin concentration.179 The
within-subject biological variation for urinary ACR in an
EMU has been reported to be 31%, compared to 36% for
urinary albumin concentration.180 The same study reported
variability for ACR of 103% and 85% in random and timed
24-hour collections, respectively.180 Intra-individual variation
for protein loss is also significantly reduced when reported as
a PCR compared to protein concentration in random urine
samples collected throughout the day (a mean reduction
from 97% to 39%).179
Why and how should a finding of albuminuria be confirmed?
Given the high biological variation and other pathological
and physiological causes of albuminuria (Table 19),143 repeat
testing to confirm albuminuria, ideally using an EMU and
laboratory testing, is recommended (Figure 16).
There has been extensive discussion in the literature about
the appropriate urine sample to use for the investigation of
protein loss. It is generally recognized that a 24-hour sample
is the definitive means of demonstrating the presence of
proteinuria. However, overnight, first void in the morning
(i.e., EMU), second void in the morning, or random sample
collections can also be used. In a systematic review random
urine PCR was shown to have better performance as a test for
ruling out significant proteinuria than as a ‘‘rule-in’’ test; the
authors suggested that positive PCR results may still require
Table 19 | Factors affecting urinary ACR
Factor Examples of effect
Preanalytical factors
Transient elevation in albuminuria Menstrual blood contamination
Symptomatic UTI181
Exercise182
Upright posture (orthostatic proteinuria)41,183
Other conditions increasing vascular permeability (e.g., septicemia)
Intraindividual variability Intrinsic biological variability180
Genetic variability184
Preanalytical storage conditions Degradation of albumin before analysisa
Non-renal causes of variability in creatinine
excretion
Age (lower in children and older people)
Race (lower in Caucasian than black people)
Muscle mass (e.g., lower in people with amputations, paraplegia, muscular dystrophy)
Gender (lower in women)
Changes in creatinine excretion Non-steady state for creatinine (AKI)
Analytical factors
Antigen excess (‘prozone’) effect Samples with very high albumin concentrations may be falsely reported as low or normal using some
assays124
Abbreviations: ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; UTI, urinary tract infection.
aSamples for urinary albumin (or total protein) measurement may be analyzed fresh, stored at 41C for up to one week, or stored at -701C for longer periods. Freezing at -201C
appears to result in loss of measurable albumin and is not recommended. When analyzing stored samples, they should be allowed to reach room temperature and
thoroughly mixed prior to analysis.142
Kidney International Supplements (2013) 3, 19–62 59
chapte r 1
confirmation with a 24-hour collection.185 If an EMU is
unavailable, subsequent samples can give a reliable indication
of the 24-hour urine protein loss.174
International Relevance
The recommendation to replace urinary total protein with
albumin as the test of choice in testing for proteinuria is
consistent with most,1,31,130,186,187 but not all,188,189 current
national and international guidance. It is accepted that cost
pressures may affect implementation of this recommendation
and may differ across the world.
Most international guidelines have also discouraged the
use of reagent strip analysis for proteinuria detec-
tion.186,189–191 Nevertheless, in the present guideline we
acknowledge that these devices may have a role, particularly
in settings where access to laboratory services may be limited.
ACRs in North America tend to be reported in mg/g
whereas in other parts of the world usage of mg/mmol
predominates. This difference appears unlikely to be resolved
in the foreseeable future. When publishing data authors
should ensure either that both units are cited or that a
conversion factor is provided.
There is increasing adoption of the term ‘albuminuria’
instead of microalbuminuria by international and national
laboratory and some clinical organizations.
Implications for Clinical Practice and Public Policy
Direct reagent costs of total protein measurement are
generally lower than those of albumin measurement, which
requires antibody-based reagents. It is often considered that
reagent strip analyses are a cheaper option. Therefore some
health-care systems may struggle to justify the recommenda-
tions in this guideline.
Costs of diagnostic tests vary depending on local financial
agreements between hospitals and suppliers. In England,
the National Institute for Health and Clinical Excellence (NICE)
sampled a small random number of laboratories and estimated
the average cost of an ACR to be d2.16 whereas a PCR cost
d1.42.186 It is acknowledged that increased use of ACR testing
may reduce the unit cost on the basis of economies of scale. In
Canada, laboratory analysis costs (Canadian dollars) of $2.81
for reagent strip, $11.67 for PCR, and $29.23 for ACR have been
cited.192 In relation to albumin-specific reagent strips, a cost of
approximately $4 for a Micral test II (Roche Diagnostics)
compared to $2 for a laboratory ACR has been reported.193
The cost- and clinical-effectiveness of an approach
utilizing reagent strip testing followed by laboratory mea-
surement compared to an approach in which samples are
submitted directly to the laboratory (for either albumin or
protein measurement) has recently been evaluated in a health
economics model.186 The model favored abandoning the use
of reagent strips for identification of proteinuria.
Areas of Controversy, Confusion, or Non-consensus
Some data suggest that ACR is a poorer predictor of 24-hour
total protein loss than PCR194 and has no advantage over
PCR as a predictor of renal outcomes and mortality in
patients with CKD.195,196 In the prediction of future
transplant rejection, PCR has been reported to have equal
utility to ACR,192 although in a separate study ACR was
found to be a better predictor.197
In the setting of preeclampsia, proteinuria is generally
defined as Z300mg/24 hours or a PCR Z300mg/g
(Z30mg/mmol).175 Currently, there is insufficient evidence
to substitute urine albumin measurement for total protein in
this setting.172
Creatinine excretion is affected by a variety of non-renal
influences (Table 19) and it therefore follows that different
cutoffs for ACR (and PCR) may be required in different
individuals.194,198 While age-related cutoffs have not gen-
erally been applied in clinical practice, clinicians should bear
this in mind when interpreting urine ACR data in older
individuals or those with very low body mass, as these will
impact the urine creatinine excretion.
While most guidelines agree that an ACR greater than
approximately 3mg/mmol (30mg/g) is pathological in the
setting of diabetes, in the non-diabetic population a higher
threshold has commonly been used to define proteinuria. In the
NICE guideline in England and Wales, proteinuria in non-
diabetic individuals was defined asZ30mg/mmol (Z300mg/g),
with higher level proteinuria being 470mg/mmol (4700mg/
g).186 Confirmation of results lying between 30 and 70mg/mmol
(300-700mg/g) was recommended.186 The present guideline
proposes a lower threshold definition for albuminuria for use in
both diabetic and non-diabetic individuals.
A study from Italy in type 2 diabetes has reported that,
although intra-individual biological variation of albuminuria
is large, a single sample (either ACR or timed collection) can
accurately classify patients into albuminuria categories,
negating the need for multiple collections.178
Some data suggest that a significant proportion of
albumin present in urine may be non-immunoreactive,199–202
although this finding has been questioned.203,204
There is a substantial existing literature using the term
microalbuminuria and many existing guidelines use this term
especially in the context of diabetes and cardiovascular risk,
as its presence confers risk. Nonetheless, the Work Group
believes that it is important for this international guideline to
foster ‘best practices’ and clarity of communication, and
since the risk of adverse events is continuous throughout the
spectrum of albuminuria, we encourage adoption of the term
‘albuminuria’ with subsequent quantification of the level or
amount.
Pediatric Considerations
For Recommendation 1.4.4.1, this set of statements would need
to be altered for application in the pediatric practice as follows:
We suggest using the following measurements for initial
testing of proteinuria in children (in descending order of
preference):
(1) urine PCR, EMU sample preferred;
(2) urine ACR, EMU sample preferred;
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(3) reagent strip urinalysis for total protein with automated
reading;
(4) reagent strip urinalysis for total protein with manual
reading.
For Recommendations 1.4.4.2 and 1.4.4.3, this set of
statements would need to be altered for application in the
pediatric practice as follows:
Currently the urinary PCR should be favored over the
urine ACR in children. Unlike in adults where powerful
evidence exists in support of the use of measures of albumin
rather than total protein to predict adverse outcomes, this
level of evidence is currently lacking in children.205 However,
current longitudinal trials such as CKiD55 and European 4C78
may eventually shed light on this issue.
In children the underlying conditions associated with the
diagnosis of CKD are also important considerations as to
which form of testing is most valuable. Unlike adults where
the majority of patients with CKD are attributed to an
underlying glomerular disease or hypertensive damage, the
vast majority of children have underlying developmental
abnormalities often referred to as CAKUT (congenital
anomalies of the kidney and urinary tract).70 This relative
paucity of glomerular conditions makes the use of albumin
excretion a less sensitive test for diagnostic purposes as many
children will have underlying tubular conditions and hence
tend to excrete more Tamm-Horsfall protein and other low-
molecular-weight proteins that will not be captured by the
albumin-to-creatinine (or formal albumin excretion) assay.
For Recommendations 1.4.4.2 and 1.4.4.2.1 this guideline
is fully applicable in pediatrics. The recommendation that
clinical laboratories report ACR and PCR in untimed
urine samples in addition to albumin concentration or
proteinuria concentrations rather than the concentrations
alone is valid and useful in the pediatric population. As per
Recommendation 1.2.4, however, note should be made
that age-related normal values for urinary protein losses
must be considered when laboratories choose to report either
ACR or PCR.
Albuminuria in children, whether measured as an absolute
value per day, an excretion rate, or as an albumin to
creatinine ratio is fraught with more uncertainity than in
adults as they are known to vary across categories of age, sex,
height, weight, and Tanner staging.206
In two recent reviews by Rademacher206 and Tsioufis et al.,205
both groups examined the results of all relevant studies on
normative values of AER or ACR. Rademacher’s paper in
particular provides detailed information on the mean AER
values (with SD) across a variety of studies, ages, sex, and race,
and provides a normative estimate for overnight AER of
between 2-6mg/minute or a 95th percentile value from 4.5–28mg/
minute. Similarly, they summarize results for ACR in normal
children and suggest that the mean for children older than 6
years would seem to fall between 8-10mg/g (0.8-1.0mg/mmol).
For Recommendation 1.4.4.3, this guideline is fully
applicable in pediatrics.
1.4.4.4: If significant non-albumin proteinuria is sus-
pected, use assays for specific urine proteins
(e.g., a1-microglobulin, monoclonal heavy or
light chains, [known in some countries as
‘‘Bence Jones’’proteins]). (Not Graded)
RATIONALE
Testing for tubular proteinuria using a total protein approach
almost certainly has very poor sensitivity for detecting
tubular disease. When an isolated tubular lesion is suspected
(Table 3), this is probably best investigated by measuring a
specific tubular protein (e.g., a1-microglobulin) using an
immunoassay approach.
Evidence Base
There have been concerns that replacing urinary total protein
measurement with albumin measurement may cause non-
albuminuric (effectively tubular and overproduction) pro-
teinuria to be missed. Low-molecular-weight proteinuria is a
defining feature in some uncommon kidney diseases (e.g.,
Dent’s disease).207 However, for some of the reasons already
discussed, total protein assays will also be poor at detecting
tubular proteinuria. When investigating patients for tubular
proteinuria, it is advisable to use assays targeted at specific
tubular proteins.
In the AusDiab study, of those with proteinuria (2.4% of the
general population, defined as a PCR 423mg/mmol [230mg/
g]) 92% had albuminuria (defined as an ACR 43.4mg/mmol
[34mg/g]); 8% had an ACR within the reference range.208 These
individuals were less likely to have diabetes than those with both
proteinuria and albuminuria, but no further information is
available as to the nature of the proteinuria in these individuals
or its likely significance. The authors speculate that these
individuals could have had light chain proteinuria or interstitial
nephropathies. Using albuminuria testing to identify proteinur-
ia had a specificity of 95%. The negative predictive value was
99.8% and the positive predictive value was 32.4%. The authors
concluded that testing for albuminuria rather than proteinuria
was supported.
As discussed above, quite significant increases in urinary
albumin loss have to occur before such an increase is
detectable on the background of a total protein assay. The
situation is even more extreme for tubular proteins which, in
health, are present in urine at lower concentrations than
albumin (e.g., normal daily losses of retinol binding protein,
a1-microglobulin and b2-microglobulin are 0.08, 3.6, and
0.1mg/d, respectively).209 This problem will be exacerbated
by the fact that the recognition of tubular proteins by some
total protein assays is poor.210
In disease states concentrations of tubular proteins, at least
collectively, can reach levels detectable by total protein assays.
For example, among patients with tubulointerstitial disease
but without renal insufficiency, median concentrations of a1-
microglobulin were 37mg/l, with concentrations up to 100mg/l
being observed; higher concentrations were seen in patients with
decreased GFR.211 Among a group of patients with acute
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tubular necrosis requiring dialysis treatment, median a1-
microglobulin concentration was 35mg/mmol of creatinine.212
However, although tubular proteinuria is characterized by a
relative increase in low-molecular-weight protein concentra-
tions, generally albumin still remains a significant component of
the total protein concentration. Indeed, it is thought that
tubular disease results in an increase in albumin loss as a result
of decreased tubular reabsorption of filtered albumin. For
example, it has been estimated that when tubular absorption
fails completely, b2-microglobulin loss increases to 180mg/24
hours (approximately 1800-fold normal) but there will also be
an increase in urinary albumin loss to about 360mg/24 hours
(approximately 20-fold normal).209 In a series of patients with
Dent’s disease, a classical tubular disorder, 21 of the 23 patients
demonstrating increased urinary a1-microglobulin and b2-
microglobulin loss also had increased urinary albumin loss:
those who did not had borderline increases in tubular protein
losses that would not have been detectable using a total protein
measurement approach.207 The authors comment that in those
patients in whom proteinuria was marked (41 g/d), urinary
albumin loss was also markedly increased. In some situations,
however, tubular proteinuria in the absence of albuminuria has
been reported (e.g., in some children with type 1 diabetes213 and
in kidney scarring in reflux nephropathy214).
International Relevance
There is no reason to believe that there are significant
differences around the world with respect to incidence or
prevalence of conditions in which measurement of non-
albumin proteins would be required. The availability of
reliable tests for these alternative proteins, however, may be
different in different regions.
Implications for Clinical Practice and Public Policy
The incidence and prevalence of tubular disorders will vary
geographically with the clinical setting (e.g., adult or
pediatric practice) and factors such as occupational exposure.
Clinicians should agree with their local laboratories a suitable
approach to the detection of tubular proteinuria and
laboratories should be able to advise on suitable sample
handling procedures. It is acknowledged that many labora-
tories do not currently offer assays of tubular proteins.
In patients with suspected myeloma, monoclonal
heavy or light chains (known in some countries as Bence
Jones) protein should be sought in concentrated urine using
electrophoresis with immunofixation of any identified
protein bands in accordance with current myeloma guide-
lines.215 Simultaneous albumin measurement is needed when
the possibility of immunoglobulin light chain (AL) amyloid
or light chain deposition disease is suspected.
Non-albumin proteinuria may also be suspected in
patients with disorders of tubular function (see Table 3).
Areas of Controversy, Confusion, or Non-consensus
Testing for proteinuria using a urine albumin rather than
total protein first-line approach may occasionally miss cases
of tubular proteinuria but the significance of this problem is
probably overestimated and should be the subject of further
research.
Earlier guidance from KDOQI1 suggested that proteinuria
in children should be detected with total protein rather than
albumin assays due to the higher prevalence of non-
glomerular diseases in this group of patients. For the reasons
outlined above, we do not think total protein assays are
suitable for this purpose and would ideally recommend
testing for albumin and for specific tubular proteins when
non-glomerular disease is suspected.
Pediatric Considerations
For Recommendation 1.4.4.4, this statement is fully applic-
able in pediatrics. In children the likelihood of any form of
overflow proteinuria such as seen in conditions of heavy or
light chain production is extremely low; however a significant
number of underlying genetic tubular disorders do exist and
protein electrophoresis can assist the practitioner in deter-
mining the presence of such a condition or the concurrent
finding of severe tubular injury in addition to a glomerular
condition.
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